U.S. patent number 10,570,147 [Application Number 16/000,108] was granted by the patent office on 2020-02-25 for bicyclic compounds and methods of use.
This patent grant is currently assigned to BioTheryX, Inc.. The grantee listed for this patent is BioTheryX, Inc.. Invention is credited to Kyle W. H. Chan, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan, Eduardo Torres.
![](/patent/grant/10570147/US10570147-20200225-C00001.png)
![](/patent/grant/10570147/US10570147-20200225-C00002.png)
![](/patent/grant/10570147/US10570147-20200225-C00003.png)
![](/patent/grant/10570147/US10570147-20200225-C00004.png)
![](/patent/grant/10570147/US10570147-20200225-C00005.png)
![](/patent/grant/10570147/US10570147-20200225-C00006.png)
![](/patent/grant/10570147/US10570147-20200225-C00007.png)
![](/patent/grant/10570147/US10570147-20200225-C00008.png)
![](/patent/grant/10570147/US10570147-20200225-C00009.png)
![](/patent/grant/10570147/US10570147-20200225-C00010.png)
![](/patent/grant/10570147/US10570147-20200225-C00011.png)
View All Diagrams
United States Patent |
10,570,147 |
Sullivan , et al. |
February 25, 2020 |
**Please see images for:
( Certificate of Correction ) ** |
Bicyclic compounds and methods of use
Abstract
The present invention provides compounds that modulate protein
function, specifically phosphodiesterase 4 (PDE4). The invention
provides methods of treating, ameliorating, and/or preventing
diseases, disorders, and conditions associated with PDE4.
Compositions, including in combination with other inflammatory
mediators, are also provided.
Inventors: |
Sullivan; Robert (Vista,
CA), Erdman; Paul E. (San Diego, CA), Torres; Eduardo
(San Diego, CA), Fung; Leah (San Diego, CA), Chan; Kyle
W. H. (San Diego, CA), Mercurio; Frank (Rancho Santa Fe,
CA) |
Applicant: |
Name |
City |
State |
Country |
Type |
BioTheryX, Inc. |
Chappaqua |
NY |
US |
|
|
Assignee: |
BioTheryX, Inc. (Chappaqua,
NY)
|
Family
ID: |
62749231 |
Appl.
No.: |
16/000,108 |
Filed: |
June 5, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20180354967 A1 |
Dec 13, 2018 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
62519003 |
Jun 13, 2017 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07D
495/04 (20130101); A61P 29/00 (20180101); A61P
37/00 (20180101) |
Current International
Class: |
A61K
31/4015 (20060101); A61K 31/407 (20060101); C07D
495/04 (20060101); A61P 29/00 (20060101); A61P
37/00 (20060101) |
Field of
Search: |
;514/412,443
;548/453,513 ;549/50,54 |
Foreign Patent Documents
|
|
|
|
|
|
|
2761845 |
|
Nov 2010 |
|
CA |
|
1 964 842 |
|
Sep 2008 |
|
EP |
|
2 083 011 |
|
Jul 2009 |
|
EP |
|
2 431 371 |
|
Mar 2012 |
|
EP |
|
Other References
Carey, 1992, 8.15 Sulfonate esters as substrates in nucleophilic
substitution reactions, in Organic Chemistry Second Edition,
McGraw-Hill, Inc., New York , pp. 328-331. cited by applicant .
Greene et al., eds., Protective Groups in Organic Synthesis; John
Wiley & Sons, Inc., New York, 1999. cited by applicant .
McMurray, 2000, Organic Chemistry Fifth Edition, Brooks/Cole,
Pacific Grove, CA, pp. 398, 408. cited by applicant .
McOmie ed., Protective Groups in Organic Chemistry, Plenum Press,
London and New York, 1973. cited by applicant .
Streitwieser et al., 1981, 8.10 Leaving Groups, in Introduction to
Organic Chemistry Second Edition, Macmillan Publishing Co., Inc.,
New York, pp. 169-171. cited by applicant .
International Search Report and Written Opinion dated Aug. 21, 2018
in application No. PCT/US2018/036276. cited by applicant.
|
Primary Examiner: Coughlin; Matthew P
Assistant Examiner: Patel; Sagar
Attorney, Agent or Firm: Knobbe, Martens, Olson & Bear,
LLP
Claims
What is claimed is:
1. A compound of Formula (I), or a pharmaceutically acceptable salt
thereof, ##STR00055## wherein: Y is H, deuterium, halogen, or an
optionally substituted C.sub.1-C.sub.6 alkyl; X and X.sub.1 are
each independently CH.sub.2, C.dbd.O, SO, SO.sub.2, or CH.sub.2CO;
R.sub.1 is deuterium, hydroxy, halogen, cyano, optionally
substituted C.sub.1-C.sub.6 alkoxy, --NHR.sub.1A,
--NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C, --NR.sub.1AC(O)R.sub.1C,
--NHSO.sub.2R.sub.1C, --NR.sub.1ASO.sub.2R.sub.1C,
--N[C(O)R.sub.1A][C(O)R.sub.1C], --NHC(O)CH.sub.2OCH.sub.3, an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl; R.sub.1A and R.sub.1B are independently an
optionally substituted C.sub.3-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl; R.sub.1C is CF.sub.3, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl; R.sub.2 is hydroxy, --NH.sub.2, --NHR.sub.1A',
--NR.sub.1A.R.sub.1B', an optionally substituted C.sub.1-C.sub.6
alkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkyl, an
optionally substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, or an optionally substituted 5
to 10 membered heteroaryl; R.sub.1A' and R.sub.1B' are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, an optionally
substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, or an optionally substituted 5
to 10 membered heteroaryl; R.sub.3, R.sub.6, and R.sub.7 are
independently selected from the group consisting of a hydrogen, a
deuterium, a halogen, an optionally substituted C.sub.1-C.sub.6
alkyl, an optionally substituted C.sub.1-C.sub.6 alkoxy, an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, an optionally
substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, and an optionally substituted 5
to 10 membered heteroaryl; R.sub.4 and R.sub.5 are independently
selected from the group consisting of an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, and
an optionally substituted 5 to 10 membered heteroaryl; or R.sub.4
and R.sub.5, together with the atoms to which they are attached,
form an optionally substituted 5 or 6 membered heterocyclyl; and
R.sub.8 is hydrogen or deuterium.
2. The compound of claim 1, wherein: R.sub.1 is deuterium, hydroxy,
halogen, cyano, optionally substituted C.sub.1-C.sub.6 alkoxy,
--NHR.sub.1A, --NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C,
--NR.sub.1AC(O)R.sub.1C, --NHSO.sub.2R.sub.1C,
--NR.sub.1ASO.sub.2R.sub.1C, an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, or
an optionally substituted 5 to 10 membered heteroaryl; wherein,
when a C.sub.1-C.sub.6 alkyl, a C.sub.1-C.sub.6 alkoxy, a
C.sub.3-C.sub.6 cycloalkyl, a C.sub.6-C.sub.10 aryl, a 3 to 10
membered heterocyclyl, or a 5 to 10 membered heteroaryl is
substituted, the substituted substituents are independently
selected from the group consisting of a deuterium, an oxo, a
halogen, cyano, a nitro, an optionally substituted C.sub.1-C.sub.6
alkyl, an optionally substituted C.sub.1-C.sub.6 haloalkyl, an
optionally substituted C.sub.1-C.sub.6 alkoxy, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted
C.sub.6-C.sub.10 aryl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted 5 to 10 membered
heteroaryl, C(O)R.sub.A, C(O)OR.sub.A, --C(O)NR.sub.BR.sub.C,
--OR.sub.A, --OC(O)R.sub.A, --OC(O)NR.sub.BR.sub.C, --OS(O)R.sub.A,
--OS(O).sub.2R.sub.A, --OS(O)NR.sub.BR.sub.C,
--OS(O).sub.2NR.sub.BR.sub.C, --NR.sub.BR.sub.C,
--NR.sub.AC(O)R.sub.A, --NR.sub.AC(O)OR.sub.A,
--NR.sub.AC(O)NR.sub.BR.sub.C, --NR.sub.AS(O)R.sub.A,
--NR.sub.AS(O).sub.2R.sub.A, --NR.sub.AS(O)NR.sub.BR.sub.C,
--NR.sub.AS(O).sub.2NR.sub.BR.sub.C, --SR.sub.A, --S(O)R.sub.A,
--S(O).sub.2R.sub.A, --S(O)NR.sub.BR.sub.C, and
--S(O).sub.2NR.sub.BR.sub.C; and each R.sub.A, R.sub.B, and R.sub.C
is independently selected from the group consisting of a hydrogen,
a deuterium, an unsubstituted C.sub.1-C.sub.6 alkyl, an
unsubstituted C.sub.2-C.sub.6 alkenyl, an unsubstituted
C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10 membered
heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, and an
unsubstituted 5 to 10 membered heteroaryl; or R.sub.B and R.sub.C,
together with the nitrogen atom to which they are attached, form an
optionally substituted 3 to 10 membered heterocyclyl.
3. The compound of claim 1, wherein one of X and X.sub.1 is
CH.sub.2 and the other is C.dbd.O.
4. The compound of claim 1, wherein X is C.dbd.O and X.sub.1 is
CH.sub.2.
5. The compound of claim 1, wherein X and X.sub.1 are each
C.dbd.O.
6. The compound of claim 1, wherein R.sub.1 is --NHR.sub.1A,
--NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C,
--N[C(O)R.sub.1A][C(O)R.sub.1C], or --NR.sub.1AC(O)R.sub.1C.
7. The compound of claim 6, wherein R.sub.1 is
--NHC(O)R.sub.1C.
8. The compound of claim 1, wherein R.sub.1A and R.sub.1B are
independently an optionally substituted C.sub.3-C.sub.6 alkyl or an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, and wherein
R.sub.1C is an optionally substituted C.sub.3-C.sub.6
cycloalkyl.
9. The compound of claim 1, wherein R.sub.3, R.sub.6, and R.sub.7
are independently selected from the group consisting of a hydrogen,
a halogen, and an optionally substituted C.sub.1-C.sub.6 alkyl.
10. The compound of claim 9, wherein R.sub.3, R.sub.6, and R.sub.7
are each hydrogen.
11. The compound of claim 1, wherein R.sub.2 is an optionally
substituted C.sub.1-C.sub.6 alkyl.
12. The compound of claim 1, wherein R.sub.2 is an unsubstituted
C.sub.1-C.sub.6 alkyl.
13. The compound of claim 1, wherein R.sub.4 and R.sub.5, together
with the atoms to which they are attached, form an optionally
substituted 5 or 6 membered heterocyclyl.
14. The compound of claim 1, wherein R.sub.8 is hydrogen.
15. A compound selected from the group consisting of: ##STR00056##
##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## or
a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising a compound of claim 1,
or a pharmaceutically acceptable salt thereof, and at least one
pharmaceutically acceptable carrier.
17. A method of treating, or ameliorating a disease, disorder, or
condition associated with TNF-.alpha., INF-.gamma., IL-2, IL-17, or
IL-23, or a combination thereof, to a subject in need thereof,
comprising administering a therapeutically effective amount of a
compound of claim 1, or a pharmaceutically acceptable salt thereof,
to the said subject; wherein the disease, disorder, or condition is
selected from the group consisting of arthritis, ankylosing
spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's
disease, an inflammatory bowel disease, psoriasis, psoriatic
arthritis, atopic dermatitis, and contact dermatitis, or
combinations thereof.
18. A method of treating, or ameliorating a disease, disorder, or
condition associated with PDE4, to a subject in need thereof,
comprising administering a therapeutically effective amount of a
compound of claim 1, or a pharmaceutically acceptable salt thereof,
to the said subject; wherein the disease, disorder, or condition is
selected from the group consisting of arthritis, ankylosing
spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's
disease, an inflammatory bowel disease, psoriasis, psoriatic
arthritis, atopic dermatitis, and contact dermatitis, or
combinations thereof.
19. A method of decreasing expression of a protein selected from
TNF-.alpha., INF-.gamma., IL-2, IL-17, IL-23, or a combination
thereof, comprising contacting a cell with a compound of claim 1,
or a pharmaceutically acceptable salt thereof.
20. The method of claim 19, wherein the protein is TNF-.alpha..
21. A method of inhibiting PDE4 activity, comprising contacting a
cell with a compound of claim 1, or a pharmaceutically acceptable
salt thereof.
22. A method of treating psoriasis to a subject in need thereof,
comprising topically administering a therapeutically effective
amount of a pharmaceutical composition of claim 16, to the said
subject.
23. The compound of claim 5, wherein R.sub.1 is --NHR.sub.1A,
--NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C,
--N[C(O)R.sub.1A][C(O)R.sub.1C], or --NR.sub.1AC(O)R.sub.1C.
24. The compound of claim 23, wherein R.sub.1A and R.sub.1B are
independently an optionally substituted C.sub.3-C.sub.6 alkyl or an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, and wherein
R.sub.1C is CF.sub.3 or an optionally substituted C.sub.3-C.sub.6
cycloalkyl.
25. The compound of claim 24, wherein R.sup.2 is an optionally
substituted C.sub.1-C.sub.6 alkyl, --NH(C.sub.1-6 alkyl), or
--N(C.sub.1-6 alkyl).sub.2.
26. The compound of claim 25, wherein R.sub.3, R.sub.6, and R.sub.7
are independently a hydrogen, a halogen, or an optionally
substituted C.sub.1-C.sub.6 alkyl.
27. The compound of claim 26, wherein R.sub.4 and R.sub.5 are
independently an optionally substituted C.sub.1-C.sub.6 alkyl.
28. The compound of claim 26, wherein R.sub.4 and R.sub.5, together
with the atoms to which they are attached, form an optionally
substituted 5 or 6 membered heterocyclyl.
29. The compound of claim 1, wherein R.sub.1C is --CF.sub.3 or an
optionally substituted C.sub.3-C.sub.6 cycloalkyl.
30. The compound of claim 7, wherein R.sub.1C is an optionally
substituted C.sub.3-C.sub.6 cycloalkyl.
Description
BACKGROUND OF THE INVENTION
Field of the Invention
Compounds, methods of making such compounds, pharmaceutical
compositions and medicaments comprising such compounds, and methods
of using such compounds to treat, prevent or diagnose diseases,
disorders, or conditions associated with phosphodiesterase 4 (PDE4)
malfunction are provided.
Description of the Related Technology
Aberrant protein function, and/or protein imbalance is a hallmark
of many disease states. For example, the functioning of the immune
system is finely balanced by the activities of pro-inflammatory and
anti-inflammatory mediators or cytokines. Some cytokines promote
inflammation (pro-inflammatory cytokines), whereas other cytokines
suppress the activity of the pro-inflammatory cytokines
(anti-inflammatory cytokines). For example, IL-4, IL-10, and IL-13
are potent activators of B lymphocytes, and also act as
anti-inflammatory agents. They are anti-inflammatory cytokines by
virtue of their ability to suppress genes for pro-inflammatory
cytokines such as IL-1, TNF, and chemokines.
Unregulated activities of these mediators can lead to the
development of serious inflammatory conditions. For example,
autoimmune diseases arise when immune system cells (lymphocytes,
macrophages) become sensitized against the "self." Lymphocytes, as
well as macrophages, are usually under control in this system.
However, a misdirection of the system toward the body's own tissues
may happen in response to still unexplained triggers. One
hypothesis is that lymphocytes recognize an antigen which mimics
the "self" and a cascade of activation of different components of
the immune system takes place, ultimately leading to tissue
destruction. Genetic predisposition has also been postulated to be
responsible for autoimmune disorders.
For example, phosphodiesterase 4 (PDE4) is involved in the cytokine
production of inflammatory cells, angiogenesis, and the functional
properties of other cell types such as keratinocytes, in part,
through degradation of cyclic adenosine monophosphate (cAMP). cAMP
is an important second messenger that regulates inflammatory
responses. Accordingly, inhibitors of PDE4 may block the synthesis
of several pro-inflammatory cytokines and chemokines, such as tumor
necrosis factor alpha, interleukin 23, CXCL9, and CXCL10 in
multiple cell types, and may interfere with the production of
leukotriene B4, inducible nitric oxide synthase, and matrix
metalloproteinases. This interference reduces certain inflammatory
processes, such as dendritic cell infiltration, epidermal skin
thickening, and joint destruction, for example in psoriasis and
other inflammatory and/or autoimmune diseases such as arthritis,
ankylosing spondylitis, osteoarthritis, rheumatoid arthritis,
Behcet's disease, inflammatory bowel diseases (e.g., Crohn's
disease and ulcerative colitis), psoriasis, atopic dermatitis, and
contact dermatitis.
Psoriasis is an autoimmune skin disease caused by pro-inflammatory
cytokines, interferon gamma (IFN-.gamma.) and TNF-.alpha.. The
psoriatic immune response involves monocytes, dendritic cells,
neutrophils and T cells, which all contribute to aberrant
keratinocyte proliferation. PDE4 inhibition may reduce production
of multiple mediators including TNF-.alpha., IFN-.gamma., CXCL9
(monokine induced by IFN-.gamma., or MIG), CXCL10
(IFN-.gamma.-induced protein of 10 kDa, or IP-10), IL-2, IL-12,
IL-23, macrophage inflammatory protein-1-alpha (MIP-1.alpha.),
monocyte chemoattractant protein-1 and granulocyte
macrophage-colony stimulating factor (GM-CSF) from PBMCs. Thus,
there is a need for small molecule PDE4 inhibitors.
SUMMARY OF THE INVENTION
The compounds disclosed in the present application have been
discovered to exert surprising and unexpected biological effects.
In particular, the compounds disclosed in the present application
may reduce inflammation, cellular cAMP levels, and inhibit
PDE4.
Some embodiments provide a compound of Formula (I), Formula (II),
or a pharmaceutically acceptable salt of any of the foregoing,
##STR00001##
In some embodiments, X and X.sub.1 are each independently CH.sub.2,
C.dbd.O, SO, SO.sub.2, or CH.sub.2CO.
In some embodiments, Y is H, deuterium, halogen, or an optionally
substituted C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sub.1 is H, deuterium, hydroxy, halogen,
nitro, cyano, optionally substituted C.sub.1-C.sub.6 alkoxy,
--NH.sub.2, --NHR.sub.1A, --NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C,
--NR.sub.1AC(O)R.sub.1C, --NHSO.sub.2R.sub.1C,
--NR.sub.1ASO.sub.2R.sub.1C, --N[C(O)R.sub.1A][C(O)R.sub.1C], an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl.
In some embodiments, R.sub.1A, R.sub.1B, and R.sub.1C are
independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, or
an optionally substituted 5 to 10 membered heteroaryl.
In some embodiments, R.sub.2 is hydroxy, --NH.sub.2, --NHR.sub.1A,
--NR.sub.1AR.sub.1B, an optionally substituted C.sub.1-C.sub.6
alkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkyl, an
optionally substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, or an optionally substituted 5
to 10 membered heteroaryl.
In some embodiments, R.sub.3, R.sub.6, and R.sub.7 are
independently selected from a hydrogen, a deuterium, a halogen, an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.1-C.sub.6 alkoxy, an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, and an optionally substituted 5 to 10 membered
heteroaryl.
In some embodiments, R.sub.4 and R.sub.5 are independently selected
from an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, and an optionally substituted 5 to 10
membered heteroaryl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an optionally substituted 5 or 6
membered heterocyclyl.
In some embodiments, R.sub.8 is hydrogen or deuterium. In some
embodiments, R.sub.8 is hydrogen. In other embodiments, R.sub.8 is
deuterium.
In some embodiments, when R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl, at least one of R.sub.4 and R.sub.5 is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, an optionally
substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, an optionally substituted 5 to
10 membered heteroaryl, or R.sub.4 and R.sub.5, together with the
atoms to which they are attached, form an optionally substituted 5
or 6 membered heterocyclyl. In some embodiments, when R.sub.2 is an
optionally substituted C.sub.1-C.sub.4 alkyl or NH(C.sub.1-C.sub.6
alkyl), at least one of R.sub.4 and R.sub.5 is an optionally
substituted cyclopropyl. In some embodiments, when R.sub.4 and
R.sub.5 are each independently an optionally substituted
C.sub.1-C.sub.6 alkyl, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, or an optionally substituted 5 to 10 membered heteroaryl. In
some embodiments, R.sub.2, R.sub.4, and R.sub.5 are not all an
optionally substituted C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sub.2 is hydroxy, --NH.sub.2, --NHR.sub.1A,
or --NR.sub.1AR.sub.1B, and R.sub.4 and R.sub.5 are each
independently an optionally substituted C.sub.1-C.sub.6 alkyl, or
R.sub.4 and R.sub.5, together with the atoms to which they are
attached, form an optionally substituted 5 or 6 membered
heterocyclyl.
In some embodiments, when a C.sub.1-C.sub.6 alkyl, a
C.sub.1-C.sub.6 alkoxy, a C.sub.3-C.sub.6 cycloalkyl, a
C.sub.6-C.sub.10 aryl, a 3 to 10 membered heterocyclyl, or a 5 to
10 membered heteroaryl is substituted, the substituted substituents
are independently selected from a deuterium, an oxo, a halogen,
cyano, a nitro, an optionally substituted C.sub.1-C.sub.6 alkyl, an
optionally substituted C.sub.1-C.sub.6 haloalkyl, an optionally
substituted C.sub.1-C.sub.6 alkoxy, an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted
C.sub.6-C.sub.10 aryl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted 5 to 10 membered
heteroaryl, --C(O)R.sub.A, --C(O)OR.sub.A, --C(O)NR.sub.BR.sub.C,
--OR.sub.A, --OC(O)R.sub.A, --OC(O)NR.sub.BR.sub.C, --OS(O)R.sub.A,
--OS(O).sub.2R.sub.A, --OS(O)NR.sub.BR.sub.C,
--OS(O).sub.2NR.sub.BR.sub.C, --NR.sub.BR.sub.C,
--NR.sub.AC(O)R.sub.A, --NR.sub.AC(O)OR.sub.A,
--NR.sub.AC(O)NR.sub.BR.sub.C, --NR.sub.AS(O)R.sub.A,
--NR.sub.AS(O).sub.2R.sub.A, --NR.sub.AS(O)NR.sub.BR.sub.C,
--NR.sub.AS(O).sub.2NR.sub.BR.sub.C, --SR.sub.A, --S(O)R.sub.A,
--S(O).sub.2R.sub.A, --S(O)NR.sub.BR.sub.C, and
--S(O).sub.2NR.sub.BR.sub.C.
In some embodiments, each R.sub.A, R.sub.B, and R.sub.C are
independently selected from a hydrogen, an unsubstituted
C.sub.1-C.sub.6 alkyl, an unsubstituted C.sub.2-C.sub.6 alkenyl, an
unsubstituted C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10
membered heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, and
an unsubstituted 5 to 10 membered heteroaryl.
In some embodiments, R.sub.B and R.sub.C, together with the
nitrogen atom to which they are attached, form an optionally
substituted 3 to 10 membered heterocyclyl.
In some embodiments, Y is H. In some embodiments, Y is deuterium.
In some embodiments, Y is halogen. In some embodiments, Y is an
optionally substituted C.sub.1-C.sub.6 alkyl.
In some embodiments, one of X and X.sub.1 is CH.sub.2 and the other
is C.dbd.O. In some embodiments, X and X.sub.1 are each CH.sub.2.
In some embodiments, X and X.sub.1 are each C.dbd.O. In some
embodiments, one of X and X.sub.1 is CH.sub.2 and the other is SO.
In some embodiments, one of X and X.sub.1 is CH.sub.2 and the other
is SO.sub.2. In some embodiments, one of X and X.sub.1 is CH.sub.2
and the other is CH.sub.2CO. In some embodiments, one of X and
X.sub.1 is C.dbd.O and the other one of X and X.sub.1 is SO. In
some embodiments, one of X and X.sub.1 is C.dbd.O and the other one
of X and X.sub.1 is SO.sub.2. In some embodiments, one of X and
X.sub.1 is C.dbd.O and the other is CH.sub.2CO.
In some embodiments, R.sub.1 is --NHR.sub.1A, --NR.sub.1AR.sub.1B,
--NHC(O)R.sub.1C or --NR.sub.1AC(O)R.sub.1C. In some embodiments,
R.sub.1 is --N[C(O)R.sub.1A][C(O)R.sub.1C]. In some embodiments,
R.sub.1 is --NHC(O)R.sub.1C. In some embodiments, R.sub.1A,
R.sub.1B, and R.sub.1C are independently an optionally substituted
C.sub.1-C.sub.6 alkyl or an optionally substituted C.sub.3-C.sub.6
cycloalkyl. In some embodiments, R.sub.1C is an optionally
substituted C.sub.1-C.sub.6 alkyl. In some embodiments, R.sub.1C is
an unsubstituted C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sub.3, R.sub.6, and R.sub.7 are
independently selected from a hydrogen, a halogen, and an
optionally substituted C.sub.1-C.sub.6 alkyl. In some embodiments,
R.sub.3, R.sub.6, and R.sub.7 are each hydrogen.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl and one of R.sub.4 and R.sub.5 is an
optionally substituted C.sub.1-C.sub.6 alkyl and the other is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl or an optionally
substituted 3 to 10 membered heterocyclyl.
In some embodiments, R.sub.2 is an unsubstituted C.sub.1-C.sub.6
alkyl and one of R.sub.4 and R.sub.5 is an unsubstituted
C.sub.1-C.sub.6 alkyl and the other is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl or an optionally substituted 3 to 10
membered heterocyclyl.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, or an optionally substituted 5 to 10 membered heteroaryl, and
R.sub.4 and R.sub.5 are independently an optionally substituted
C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, or an optionally substituted 5 to 10 membered heteroaryl, and
R.sub.4 and R.sub.5 are independently unsubstituted C.sub.1-C.sub.6
alkyl.
In some embodiments, R.sub.2 is hydroxy, --NH.sub.2, --NHR.sub.1A,
or --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are each
independently an optionally substituted C.sub.1-C.sub.6 alkyl or an
optionally substituted C.sub.6-C.sub.10 aryl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an optionally substituted 5 or 6
membered heterocyclyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an unsubstituted 5 or 6 membered
heterocyclyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an unsubstituted 5 membered
heterocyclyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an unsubstituted 6 membered
heterocyclyl.
In some embodiments, the compound Formula (I) or the compound of
Formula (II) is selected from:
##STR00002## ##STR00003## ##STR00004## ##STR00005## ##STR00006##
##STR00007## ##STR00008## ##STR00009## or a pharmaceutically
acceptable salt of any of the foregoing.
In some embodiments, the compound is a pharmaceutically acceptable
salt.
Some embodiments provide a pharmaceutical composition comprising a
compound of any of Formula (I), Formula (II), or a pharmaceutically
acceptable salt of any of the foregoing, and at least one
pharmaceutically acceptable carrier.
In some embodiments, the composition is formulated for oral,
parenteral, topical, ophthalmic, inhalation, nasal, or intravenous
administration. In some embodiments, the composition is formulated
as a tablet or capsule.
In some embodiments, the pharmaceutical composition further
comprises a second therapeutic agent. In some embodiments, the
second therapeutic agent is selected from the group consisting of
anti-inflammatory agents, anti-cancer agents, immunostimulatory
agents, and immunosuppressive agents. In some embodiments, the
second therapeutic agent is anti-inflammatory agent or an
immunosuppressive agent.
Some embodiments provide a method of treating, ameliorating, or
preventing a disease, disorder, or condition associated with
TNF-.alpha., INF-.gamma., IL-2, IL-17, IL-23, or a combination
thereof, comprising administering a therapeutically effective
amount of a compound of any one of Formula (I), Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing, or a
composition comprising any one of Formula (I) or Formula (II) to a
subject in need thereof.
In some embodiments, the disease, disorder, or condition is
selected from the group consisting of arthritis, ankylosing
spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's
disease, inflammatory bowel diseases (e.g., Crohn's disease and
ulcerative colitis), psoriasis, psoriatic arthritis, atopic
dermatitis, contact dermatitis, and combinations thereof.
Some embodiments provide a method of treating, ameliorating, or
preventing a disease, disorder, or condition associated with PDE4,
comprising administering a therapeutically effective amount of a
compound of any one of Formula (I), Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing, or a
composition comprising any one of Formula (I) or Formula (II) to a
subject in need thereof.
In some embodiments, the disease, disorder, or condition is
selected from the group consisting of arthritis, ankylosing
spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's
disease, inflammatory bowel diseases (e.g., Crohn's disease and
ulcerative colitis), psoriasis, psoriatic arthritis, atopic
dermatitis, contact dermatitis, and combinations thereof.
In some embodiments, the compound or composition is administered in
combination with a second therapeutic agent.
In some embodiments, the second therapeutic agent is selected from
the group consisting of anti-inflammatory agents, anti-cancer
agents, immunostimulatory agents, and immunosuppressive agents. In
some embodiments, the second therapeutic agent is an
anti-inflammatory agent or an immunosuppressive agent.
Some embodiments provide a method of decreasing expression of a
protein selected from TNF-.alpha., INF-.gamma., IL-2, IL-17, IL-23,
or a combination thereof, comprising contacting a cell with a
compound of any one of Formula (I) or Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing. In some
embodiments, the protein is TNF-.alpha..
Some embodiments provide a method of inhibiting PDE4 activity,
comprising contacting a cell with a compound of any one of Formula
(I) or Formula (II), or a pharmaceutically acceptable salt of any
of the foregoing.
Some embodiments provide a method of treating psoriasis, comprising
topically administering a therapeutically effective amount of a
composition comprising any one of Formula (I) or Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing, to a
subject in need thereof.
In some embodiments, the subject is known to possess wild-type
PDE4. In some embodiments, the subject is known to possess
wild-type TNF-.alpha.. In some embodiments, the subject is known to
possess wild-type INF-.gamma., IL-2, IL-17, or IL-23. In some
embodiments, the subject is known to possess aberrant PDE4. In some
embodiments, the subject is known to possess aberrant TNF-.alpha..
In some embodiments, the subject is known to possess aberrant
INF-.gamma., IL-2, IL-17, or IL-23.
In some embodiments, the cell is known to possess wild-type PDE4.
In some embodiments, the cell is known to possess wild-type
TNF-.alpha.. In some embodiments, the cell is known to possess
wild-type INF-.gamma., IL-2, IL-17, or IL-23. In some embodiments,
the cell is known to possess aberrant PDE4. In some embodiments,
the cell is known to possess aberrant TNF-.alpha.. In some
embodiments, the cell is known to possess aberrant INF-.gamma.,
IL-2, IL-17, or IL-23.
Any of the features of an embodiment is applicable to all
embodiments identified herein. Moreover, any of the features of an
embodiment is independently combinable, partly or wholly with other
embodiments described herein in any way, e.g., one, two, or three
or more embodiments may be combinable in whole or in part. Further,
any of the features of an embodiment may be made optional to other
embodiments. Any embodiment of a method can comprise another
embodiment of a compound, and any embodiment of a compound can be
configured to perform a method of another embodiment.
DETAILED DESCRIPTION
Definitions
Unless defined otherwise, all technical and scientific terms used
herein have the same meaning as is commonly understood by one of
ordinary skill in the art. All patents, applications, published
applications and other publications referenced herein are
incorporated by reference in their entirety unless stated
otherwise. In the event that there are a plurality of definitions
for a term herein, those in this section prevail unless stated
otherwise. As used in the specification and the appended claims,
the singular forms "a," "an" and "the" include plural referents
unless the context clearly dictates otherwise. Unless otherwise
indicated, conventional methods of mass spectroscopy, NMR, HPLC,
protein chemistry, biochemistry, recombinant DNA techniques and
pharmacology are employed.
The section headings used herein are for organizational purposes
only and are not to be construed as limiting the subject matter
described.
The term "protein malfunction," as used herein, refers to a protein
or proteins not properly performing its intended biological
function. For example, overexpression or underexpression and
mutations in structure/function constitute a protein malfunction.
Likewise, a protein or proteins that are expressed normally, and
function normally, but are unable to perform their intended
biological function (i.e., suppress tumor growth) are also
malfunctioning proteins.
The terms "co-administration" and similar terms as used herein are
broad terms, and are to be given their ordinary and customary
meaning to a person of ordinary skill in the art (and are not to be
limited to a special or customized meaning), and refer without
limitation to administration of the selected therapeutic agents to
a single patient, and are intended to include treatment regimens in
which the agents are administered by the same or different route of
administration or at the same or different time.
The terms "effective amount" and "therapeutically effective amount"
are broad terms, and are to be given their ordinary and customary
meaning to a person of ordinary skill in the art (and are not to be
limited to a special or customized meaning), and refer without
limitation to a sufficient amount of an agent or a compound being
administered which will relieve to some extent one or more of the
symptoms of the disease or condition being treated. The result can
be reduction and/or alleviation of the signs, symptoms, or causes
of a disease, or any other desired alteration of a biological
system. For example, an "effective amount" for therapeutic uses is
the amount of the composition comprising a compound as disclosed
herein required to provide a clinically significant decrease in
disease symptoms. An appropriate "effective" amount in any
individual case may be determined using techniques, such as a dose
escalation study. Where a drug has been approved by the U.S. Food
and Drug Administration (FDA) or a counterpart foreign medicines
agency, a "therapeutically effective amount" an optionally refers
to the dosage approved by the FDA or its counterpart foreign agency
for treatment of the identified disease or condition.
The term "pharmaceutical combination" as used herein is a broad
term, and is to be given its ordinary and customary meaning to a
person of ordinary skill in the art (and is not to be limited to a
special or customized meaning), and refers without limitation to a
product that results from the mixing or combining of more than one
active ingredient and includes both fixed and non-fixed
combinations of the active ingredients. The term "fixed
combination" means that the active ingredients, e.g., a compound of
a preferred embodiment and a co-agent, are both administered to a
patient simultaneously in the form of a single entity or dosage.
The term "non-fixed combination" means that the active ingredients,
e.g., a compound of a preferred embodiment and a co-agent, are
administered to a patient as separate entities either
simultaneously, concurrently or sequentially with no specific
intervening time limits, wherein such administration provides
effective levels of the two compounds in the body of the patient.
The latter also applies to cocktail therapy, e.g., the
administration of three or more active ingredients.
As used herein, any "R" group(s) such as, without limitation,
R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.9, and R.sub.10
represent substituents that can be attached to the indicated atom.
An R group may be substituted or an unsubstituted. If two "R"
groups are described as being "taken together" the R groups and the
atoms they are attached to can form a cycloalkyl, aryl, heteroaryl,
or heterocycle. For example, without limitation, if R.sup.2 and
R.sup.3, or R.sup.2, R.sup.3, or R.sup.4, and the atom to which it
is attached, are indicated to be "taken together" or "joined
together" it means that they are covalently bonded to one another
to form a ring:
##STR00010##
Whenever a group is described as being "an optionally substituted"
that group may be an unsubstituted or substituted with one or more
of the indicated substituents. Likewise, when a group is described
as being "an unsubstituted or substituted" if substituted, the
substituent may be selected from one or more the indicated
substituents. If no substituents are indicated, it is meant that
the indicated "an optionally substituted" or "substituted" group
may be individually and independently substituted with one or more
group(s) individually and independently selected from alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, heteroaralkyl,
(heteroalicyclyl)alkyl, hydroxy, protected hydroxyl, alkoxy,
aryloxy, acyl, mercapto, alkylthio, arylthio, cyano, halogen,
thiocarbonyl, O-carbamyl, N-carbamyl, O-thiocarbamyl,
N-thiocarbamyl, C-amido, N-amido, S-sulfonamido, N-sulfonamido,
C-carboxy, protected C-carboxy, O-carboxy, isocyanato, thiocyanato,
isothiocyanato, nitro, silyl, sulfenyl, sulfinyl, sulfonyl,
haloalkyl, haloalkoxy, trihalomethanesulfonyl,
trihalomethanesulfonamido, amino, mono-substituted amino group and
di-substituted amino group, and protected derivatives thereof.
As used herein, "C.sub.a to C.sub.b" in which "a" and "b" are
integers refer to the number of carbon atoms in an alkyl, alkenyl
or alkynyl group, or the number of carbon atoms in the ring of a
cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl or
heteroalicyclyl group. That is, the alkyl, alkenyl, alkynyl, ring
of the cycloalkyl, ring of the cycloalkenyl, ring of the
cycloalkynyl, ring of the aryl, ring of the heteroaryl or ring of
the heteroalicyclyl can contain from "a" to "b", inclusive, carbon
atoms. Thus, for example, a "C.sub.1 to C.sub.4 alkyl" group refers
to all alkyl groups having from 1 to 4 carbons, that is,
CH.sub.3--, CH.sub.3CH.sub.2--, CH.sub.3CH.sub.2CH.sub.2--,
(CH.sub.3).sub.2CH--, CH.sub.3CH.sub.2CH.sub.2CH.sub.2--,
CH.sub.3CH.sub.2CH(CH.sub.3)-- and (CH.sub.3).sub.3C--. If no "a"
and "b" are designated with regard to an alkyl, alkenyl, alkynyl,
cycloalkyl cycloalkenyl, cycloalkynyl, aryl, heteroaryl or
heteroalicyclyl group, the broadest range described in these
definitions is to be assumed.
As used herein, "alkyl" refers to a straight or branched
hydrocarbon chain that comprises a fully saturated (no double or
triple bonds) hydrocarbon group. The alkyl group may have 1 to 20
carbon atoms (whenever it appears herein, a numerical range such as
"1 to 20" refers to each integer in the given range; e.g., "1 to 20
carbon atoms" means that the alkyl group may consist of 1 carbon
atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20
carbon atoms, although the present definition also covers the
occurrence of the term "alkyl" where no numerical range is
designated). The alkyl group may also be a medium size alkyl having
1 to 10 carbon atoms. The alkyl group could also be a lower alkyl
having 1 to 6 carbon atoms. The alkyl group of the compounds may be
designated as "C.sub.1-C.sub.4 alkyl" or similar designations. By
way of example only, "C.sub.1-C.sub.4 alkyl" indicates that there
are one to four carbon atoms in the alkyl chain, i.e., the alkyl
chain is selected from methyl, ethyl, propyl, iso-propyl, n-butyl,
iso-butyl, sec-butyl, and t-butyl. Typical alkyl groups include,
but are in no way limited to, methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, tertiary butyl, pentyl, and hexyls. The alkyl
group may be substituted or an unsubstituted. Substituted alkyl
groups include, but are not limited to benzyl, substituted benzyl,
aminoalkyl, substituted aminoalkyl, carboxyalkyl, alkoxyalkyl, and
the like.
As used herein, "alkenyl" refers to an alkyl group, as defined
herein, that contains in the straight or branched hydrocarbon chain
one or more double bonds. An alkenyl group may be an unsubstituted
or substituted. Typical alkyl groups include, but are in no way
limited to, vinyl, allyl, 1-propenyl, and 2-propenyl.
As used herein, "alkynyl" refers to an alkyl group as defined
herein, that contains in the straight or branched hydrocarbon chain
one or more triple bonds. An alkynyl group may be an unsubstituted
or substituted.
As used herein, "cycloalkyl" refers to a completely saturated (no
double or triple bonds) mono- or multi-cyclic hydrocarbon ring
system. When composed of two or more rings, the rings may be joined
together in a fused, bridged, or spiro fashion. Cycloalkyl groups
can contain 3 to 10 atoms in the ring(s) or 3 to 8 atoms in the
ring(s). A cycloalkyl group may be an unsubstituted or substituted.
Typical cycloalkyl groups include, but are in no way limited to,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and
cyclooctyl.
As used herein, "cycloalkenyl" refers to a mono- or multi-cyclic
hydrocarbon ring system that contains one or more double bonds in
at least one ring; although, if there is more than one, the double
bonds cannot form a fully delocalized pi-electron system throughout
all the rings (otherwise the group would be "aryl," as defined
herein). When composed of two or more rings, the rings may be
connected together in a fused, bridged, or spiro fashion. A
cycloalkenyl group may be an unsubstituted or substituted.
As used herein, "cycloalkynyl" refers to a mono- or multi-cyclic
hydrocarbon ring system that contains one or more triple bonds in
at least one ring. If there is more than one triple bond, the
triple bonds cannot form a fully delocalized pi-electron system
throughout all the rings. When composed of two or more rings, the
rings may be joined together in a fused, bridged, or spiro fashion.
A cycloalkynyl group may be an unsubstituted or substituted.
As used herein, "carbocyclyl" or "cyclic hydrocarbyl" refers to all
carbon ring systems. Such systems can be unsaturated, can include
some unsaturation, or can contain some aromatic portion, or be all
aromatic. Carbocyclyl group can contain from 3 to 30 carbon atoms.
A carbocyclyl group may be an unsubstituted or substituted.
As used herein, "aryl" refers to a carbocyclic (all carbon)
monocyclic or multicyclic aromatic ring system (including, e.g.,
fused, bridged, or spiro ring systems where two carbocyclic rings
share a chemical bond, e.g., one or more aryl rings with one or
more aryl or non-aryl rings) that has a fully delocalized
pi-electron system throughout at least one of the rings. The number
of carbon atoms in an aryl group can vary. For example, the aryl
group can be a C.sub.6-C.sub.14 aryl group, a C.sub.6-C.sub.10 aryl
group, or a C.sub.6 aryl group. Examples of aryl groups include,
but are not limited to, benzene, naphthalene, and azulene. An aryl
group may be substituted or an unsubstituted.
As used herein, "heterocyclyl" refers to mono- or polycyclic ring
systems including at least one heteroatom (e.g., O, N, S), and up
to five heteroatoms, for example, 1, 2, 3, 4, or 5 heteroatoms.
Such systems can be unsaturated, can include some unsaturation, or
can contain some aromatic portion, or be all aromatic. A
heterocyclyl group can contain from 3 to 30 atoms. A heterocyclyl
group may be an unsubstituted or substituted. Examples of
heterocycles include, but are not limited to oxirane, aziridine,
thiirane, diazidiridine, oxaziridine, azetidine, oxetane, thietane,
oxazetidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene,
imidazoline, pyrazolidine, oxazolidine, isoxazolidine,
thiazolidine, isothiazolidine, dioxolane, dithiolane, piperidine,
tetrahydropyran, thiane, piperazine, morpholine, thiomorpholine,
dioxane, dithiane, azepine, diazepine, oxepane, dioxapane,
oxazepane, thiazepane, thiepane, azocane, diazocane, oxocane,
dioxocane, thiocane, dithiocane, oxazacane, and thiazacane. A
heterocyclyl group may be substituted or unsubstituted.
As used herein, "heteroaryl" refers to a monocyclic or multicyclic
aromatic ring system (a ring system having a least one ring with a
fully delocalized pi-electron system) that contain(s) at least
heteroatom, that is, an element other than carbon, including but
not limited to, nitrogen, oxygen, and sulfur, and at least one
aromatic ring and up to five heteroatoms, for example, 1, 2, 3, 4,
or 5 heteroatoms. The number of atoms in the ring(s) of a
heteroaryl group can vary. For example, the heteroaryl group can
contain 4 to 14 atoms in the ring(s), 5 to 10 atoms in the ring(s)
or 5 to 6 atoms in the ring(s). Furthermore, the term "heteroaryl"
includes fused ring systems where two rings, such as at least one
aryl ring and at least one heteroaryl ring, or at least two
heteroaryl rings, share at least one chemical bond. Examples of
heteroaryl rings include, but are not limited to, furan, furazan,
thiophene, benzothiophene, phthalazine, pyrrole, oxazole,
benzoxazole, 1,2,3-oxadiazole, 1,2,4-oxadiazole, thiazole,
1,2,3-thiadiazole, 1,2,4-thiadiazole, benzothiazole, imidazole,
benzimidazole, indole, indazole, pyrazole, benzopyrazole,
isoxazole, benzoisoxazole, isothiazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
purine, pteridine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, and triazine. A heteroaryl group may be
substituted or an unsubstituted.
As used herein, "heteroalicyclic" or "heteroalicyclyl" refers to
three-, four-, five-, six-, seven-, eight-, nine-, ten-, up to
18-membered monocyclic, bicyclic, and tricyclic ring system wherein
carbon atoms together with from 1 to 5 heteroatoms constitute said
ring system. A heterocycle may an optionally contain one or more
unsaturated bonds situated in such a way, however, that a fully
delocalized pi-electron system does not occur throughout all the
rings. The heteroatoms are independently selected from oxygen,
sulfur, and nitrogen. A heterocycle may further contain one or more
carbonyl or thiocarbonyl functionalities, so as to make the
definition include oxo-systems and thio-systems such as lactams,
lactones, cyclic imides, cyclic thioimides, and cyclic carbamates.
When composed of two or more rings, the rings may be joined
together in a fused, bridged, or spiro fashion. Additionally, any
nitrogens in a heteroalicyclic may be quaternized. Heteroalicyclyl
or heteroalicyclic groups may be an unsubstituted or substituted.
Examples of such "heteroalicyclic" or "heteroalicyclyl" groups
include but are not limited to, 1,3-dioxin, 1,3-dioxane,
1,4-dioxane, 1,2-dioxolane, 1,3-dioxolane, 1,4-dioxolane,
1,3-oxathiane, 1,4-oxathiin, 1,3-oxathiolane, 1,3-dithiole,
1,3-dithiolane, 1,4-oxathiane, tetrahydro-1,4-thiazine,
2H-1,2-oxazine, maleimide, succinimide, barbituric acid,
thiobarbituric acid, dioxopiperazine, hydantoin, dihydrouracil,
trioxane, hexahydro-1,3,5-triazine, imidazoline, imidazolidine,
isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone,
thiazoline, thiazolidine, morpholine, oxirane, piperidine N-oxide,
piperidine, piperazine, pyrrolidine, pyrrolidone, pyrrolidione,
4-piperidone, pyrazoline, pyrazolidine, 2-oxopyrrolidine,
tetrahydropyran, 4H-pyran, tetrahydrothiopyran, thiamorpholine,
thiamorpholine sulfoxide, thiamorpholine sulfone, and their
benzo-fused analogs (e.g., benzimidazolidinone,
tetrahydroquinoline, 3,4-methylenedioxyphenyl).
"Lower alkylene groups" are straight-chained --CH.sub.2-- tethering
groups, forming bonds to connect molecular fragments via their
terminal carbon atoms. Lower alkylene groups contain from 1 to 6
carbon atoms. Examples include but are not limited to methylene
(--CH.sub.2--), ethylene (--CH.sub.2CH.sub.2--), propylene
(--CH.sub.2CH.sub.2CH.sub.2--), and butylene
(--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--). A lower alkylene group can
be substituted by replacing one or more hydrogen of the lower
alkylene group with a substituent(s) listed under the definition of
"substituted."
As used herein, "aralkyl" and "aryl(alkyl)" refer to an aryl group,
as defined above, connected, as a substituent, via a lower alkylene
group, as described above. The lower alkylene and aryl group of an
aralkyl may be substituted or an unsubstituted. Examples include
but are not limited to benzyl, 2-phenylalkyl, 3-phenylalkyl, and
naphthylalkyl.
As used herein, "heteroaralkyl" and "heteroaryl(alkyl)" refer to a
heteroaryl group, as defined above, connected, as a substituent,
via a lower alkylene group, as defined above. The lower alkylene
and heteroaryl group of heteroaralkyl may be substituted or an
unsubstituted. Examples include but are not limited to
2-thienylalkyl, 3-thienylalkyl, furylalkyl, thienylalkyl,
pyrrolylalkyl, pyridylalkyl, isoxazolylalkyl, and imidazolylalkyl,
and their benzo-fused analogs.
A "(heteroalicyclyl)alkyl" is a heterocyclic or a heteroalicyclylic
group, as defined above, connected, as a substituent, via a lower
alkylene group, as defined above. The lower alkylene and
heterocyclic or a heterocyclyl of a (heteroalicyclyl)alkyl may be
substituted or an unsubstituted. Examples include but are not
limited to tetrahydro-2H-pyran-4-yl)methyl, (piperidin-4-yl)ethyl,
(piperidin-4-yl)propyl, (tetrahydro-2H-thiopyran-4-yl)methyl, and
(1,3-thiazinan-4-yl)methyl.
As used herein, "alkoxy" refers to the formula --OR wherein R is an
alkyl, an alkenyl, an alkynyl, a cycloalkyl, a cycloalkenyl or a
cycloalkynyl, as defined above. A non-limiting list of alkoxys is
methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy,
iso-butoxy, sec-butoxy, and tert-butoxy. An alkoxy may be
substituted or an unsubstituted.
As used herein, "acyl" refers to a hydrogen, alkyl, alkenyl,
alkynyl, or aryl, as defined above, connected, as substituents, via
a carbonyl group. Examples include formyl, acetyl, propanoyl,
benzoyl, and acryl. An acyl may be substituted or an
unsubstituted.
As used herein, "hydroxyalkyl" refers to an alkyl group in which
one or more of the hydrogen atoms are replaced by a hydroxy group.
Exemplary hydroxyalkyl groups include but are not limited to,
2-hydroxyethyl, 3-hydroxypropyl, 2-hydroxypropyl, and
2,2-dihydroxyethyl. A hydroxyalkyl may be substituted or an
unsubstituted.
As used herein, "haloalkyl" refers to an alkyl group in which one
or more of the hydrogen atoms are replaced by a halogen (e.g.,
mono-haloalkyl, di-haloalkyl, and tri-haloalkyl). Such groups
include but are not limited to, chloromethyl, fluoromethyl,
difluoromethyl, trifluoromethyl and 1-chloro-2-fluoromethyl,
2-fluoroisobutyl. A haloalkyl may be substituted or an
unsubstituted.
As used herein, "haloalkoxy" refers to an alkoxy group in which one
or more of the hydrogen atoms are replaced by a halogen (e.g.,
mono-haloalkoxy, di-haloalkoxy and tri-haloalkoxy). Such groups
include but are not limited to, chloromethoxy, fluoromethoxy,
difluoromethoxy, trifluoromethoxy and 1-chloro-2-fluoromethoxy,
2-fluoroisobutoxy. A haloalkoxy may be substituted or an
unsubstituted.
As used herein, "aryloxy" and "arylthio" refers to RO-- and RS--,
in which R is an aryl, as defined above, such as but not limited to
phenyl. Both an aryloxy and arylthio may be substituted or an
unsubstituted.
A "sulfenyl" group refers to an "--SR" group in which R can be
hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or
(heteroalicyclyl)alkyl, as defined above. A sulfenyl may be
substituted or an unsubstituted.
A "sulfinyl" group refers to an "--S(.dbd.O)--R" group in which R
can be the same as defined with respect to sulfenyl. A sulfinyl may
be substituted or an unsubstituted.
A "sulfonyl" group refers to an "SO.sub.2R" group in which R can be
the same as defined with respect to sulfenyl. A sulfonyl may be
substituted or an unsubstituted.
An "O-carboxy" group refers to a "RC(.dbd.O)O--" group in which R
can be hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl,
cycloalkynyl, aryl, heteroaryl, heteroalicyclyl, aralkyl, or
(heteroalicyclyl)alkyl, as defined herein. An O-carboxy may be
substituted or an unsubstituted.
The terms "ester" and "C-carboxy" refer to a "--C(.dbd.O)OR" group
in which R can be the same as defined with respect to O-carboxy. An
ester and C-carboxy may be substituted or an unsubstituted.
A "thiocarbonyl" group refers to a "--C(.dbd.S)R" group in which R
can be the same as defined with respect to O-carboxy. A
thiocarbonyl may be substituted or an unsubstituted.
A "trihalomethanesulfonyl" group refers to an "X.sub.3CSO.sub.2--"
group wherein X is a halogen.
A "trihalomethanesulfonamido" group refers to an
"X.sub.3CS(O).sub.2N(R.sub.A)--" group wherein X is a halogen and
R.sub.A hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl,
cycloalkenyl, cycloalkynyl, aryl, heteroaryl, heteroalicyclyl,
aralkyl, or (heteroalicyclyl)alkyl.
The term "amino" as used herein refers to a --NH.sub.2 group.
As used herein, the term "hydroxy" refers to a --OH group.
A "cyano" group refers to a "--CN" group.
The term "azido" as used herein refers to a --N.sub.3 group.
An "isocyanato" group refers to a "--NCO" group.
A "thiocyanato" group refers to a "--CNS" group.
An "isothiocyanato" group refers to an "--NCS" group.
A "mercapto" group refers to an "--SH" group.
A "carbonyl" group refers to a C.dbd.O group.
An "S-sulfonamido" group refers to a "--SO.sub.2N(R.sub.AR.sub.B)"
group in which R.sub.A and R.sub.B can be independently hydrogen,
alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl,
aryl, heteroaryl, heteroalicyclyl, aralkyl, or
(heteroalicyclyl)alkyl, as defined above. An S-sulfonamido may be
substituted or an unsubstituted.
An "N-sulfonamido" group refers to a "RSO.sub.2N(R.sub.A)--" group
in which R and R.sub.A can be independently hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as
defined above. An N-sulfonamido may be substituted or an
unsubstituted.
An "O-carbamyl" group refers to a "--OC(.dbd.O)N(R.sub.AR.sub.B)"
group in which R.sub.A and R.sub.B can be independently hydrogen,
alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl,
aryl, heteroaryl, heteroalicyclyl, aralkyl, or
(heteroalicyclyl)alkyl, as defined above. An O-carbamyl may be
substituted or an unsubstituted.
An "N-carbamyl" group refers to an "ROC(.dbd.O)N(R.sub.A)--" group
in which R and R.sub.A can be independently hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as
defined above. An N-carbamyl may be substituted or an
unsubstituted.
An "O-thiocarbamyl" group refers to a
"--OC(.dbd.S)--N(R.sub.AR.sub.B)" group in which R.sub.A and
R.sub.B can be independently hydrogen, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl,
heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined
above. An O-thiocarbamyl may be substituted or an
unsubstituted.
An "N-thiocarbamyl" group refers to an "ROC(.dbd.S)N(R.sub.A)--"
group in which R and R.sub.A can be independently hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as
defined above. An N-thiocarbamyl may be substituted or an
unsubstituted.
A "C-amido" group refers to a "--C(.dbd.O)N(R.sub.AR.sub.B)" group
in which R.sub.A and R.sub.B can be independently hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as
defined above. A C-amido may be substituted or an
unsubstituted.
An "N-amido" group refers to a "RC(.dbd.O)N(R.sub.A)--" group in
which R and R.sub.A can be independently hydrogen, alkyl, alkenyl,
alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl,
heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as defined
above. An N-amido may be substituted or an unsubstituted.
A "urea" group refers to a
"--N(R.sub.AR.sub.B)--C(.dbd.O)--N(R.sub.AR.sub.B)--" group in
which R.sub.A and R.sub.B can be independently hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as
defined above. A urea group may be substituted or an
unsubstituted.
A "thiourea" group refers to a
"--N(R.sub.AR.sub.B)--C(.dbd.S)--N(R.sub.AR.sub.B)--" group in
which R.sub.A and R.sub.B can be independently hydrogen, alkyl,
alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkynyl, aryl,
heteroaryl, heteroalicyclyl, aralkyl, or (heteroalicyclyl)alkyl, as
defined above. A thiourea group may be substituted or an
unsubstituted.
The term "halogen atom" or "halogen" as used herein, means any one
of the radio-stable atoms of column 7 of the Periodic Table of the
Elements, such as, fluorine, chlorine, bromine, and iodine.
In all of the definitions described herein, the terms used to
define a new term are as previously defined herein.
Where the numbers of substituents is not specified (e.g.,
haloalkyl), there may be one or more substituents present. For
example "haloalkyl" may include one or more of the same or
different halogens. As another example, "C.sub.1-C.sub.3
alkoxyphenyl" may include one or more of the same or different
alkoxy groups containing one, two, or three atoms.
As used herein, the abbreviations for any protective groups, amino
acids and other compounds, are, unless indicated otherwise, in
accord with their common usage, recognized abbreviations, or the
IUPAC-IUB Commission on Biochemical Nomenclature (See, Biochem.
11:942-944 (1972)).
The terms "protecting group" and "protecting groups" as used herein
refer to any atom or group of atoms that is added to a molecule in
order to prevent existing groups in the molecule from undergoing
unwanted chemical reactions. Examples of protecting group moieties
are described in T. W. Greene and P. G. M. Wuts, Protective Groups
in Organic Synthesis, 3. Ed. John Wiley & Sons, 1999, and in J.
F. W. McOmie, Protective Groups in Organic Chemistry Plenum Press,
1973, both of which are hereby incorporated by reference for the
limited purpose of disclosing suitable protecting groups. The
protecting group moiety may be chosen in such a way, that they are
stable to certain reaction conditions and readily removed at a
convenient stage using methodology known from the art. A
non-limiting list of protecting groups include benzyl; substituted
benzyl; alkylcarbonyls (e.g., t-butoxycarbonyl (BOC), acetyl, or
isobutyryl); arylalkylcarbonyls (e.g., benzyloxycarbonyl or
benzoyl); substituted methyl ether (e.g., methoxymethyl ether);
substituted ethyl ether; a substituted benzyl ether;
tetrahydropyranyl ether; silyl ethers (e.g., trimethylsilyl,
triethylsilyl, triisopropylsilyl, t-butyldimethylsilyl, or
t-butyldiphenylsilyl); esters (e.g., benzoate ester); carbonates
(e.g., methoxymethylcarbonate); sulfonates (e.g., tosylate or
mesylate); acyclic ketal (e.g., dimethyl acetal); cyclic ketals
(e.g., 1,3-dioxane or 1,3-dioxolanes); acyclic acetal; cyclic
acetal; acyclic hemiacetal; cyclic hemiacetal; cyclic dithioketals
(e.g., 1,3-dithiane or 1,3-dithiolane); and triarylmethyl groups
(e.g., trityl; monomethoxytrityl (MMTr); 4,4'-dimethoxytrityl
(DMTr); or 4,4',4''-trimethoxytrityl (TMTr)).
"Leaving group" as used herein refers to any atom or moiety that is
capable of being displaced by another atom or moiety in a chemical
reaction. More specifically, in some embodiments, "leaving group"
refers to the atom or moiety that is displaced in a nucleophilic
substitution reaction. In some embodiments, "leaving groups" are
any atoms or moieties that are conjugate bases of strong acids.
Examples of suitable leaving groups include, but are not limited
to, tosylates and halogens. Non-limiting characteristics and
examples of leaving groups can be found, for example in Organic
Chemistry, 2d ed., Francis Carey (1992), pages 328-331;
Introduction to Organic Chemistry, 2d ed., Andrew Streitwieser and
Clayton Heathcock (1981), pages 169-171; and Organic Chemistry,
5.sup.th ed., John McMurry (2000), pages 398 and 408; all of which
are incorporated herein by reference for the limited purpose of
disclosing characteristics and examples of leaving groups.
The term "pharmaceutically acceptable salt" as used herein is a
broad term, and is to be given its ordinary and customary meaning
to a person of ordinary skill in the art (and is not to be limited
to a special or customized meaning), and refers without limitation
to a salt of a compound that does not cause significant irritation
to an organism to which it is administered and does not abrogate
the biological activity and properties of the compound. In some
embodiments, the salt is an acid addition salt of the compound.
Pharmaceutical salts can be obtained by reacting a compound with
inorganic acids such as hydrohalic acid (e.g., hydrochloric acid or
hydrobromic acid), sulfuric acid, nitric acid, and phosphoric acid.
Pharmaceutical salts can also be obtained by reacting a compound
with an organic acid such as aliphatic or aromatic carboxylic or
sulfonic acids, for example formic acid, acetic acid, propionic
acid, glycolic acid, pyruvic acid, malonic acid, maleic acid,
fumaric acid, trifluoroacetic acid, benzoic acid, cinnamic acid,
mandelic acid, succinic acid, lactic acid, malic acid, tartaric
acid, citric acid, ascorbic acid, nicotinic acid, methanesulfonic
acid, ethanesulfonic acid, p-toluensulfonic acid, salicylic acid,
stearic acid, muconic acid, butyric acid, phenylacetic acid,
phenylbutyric acid, valproic acid, 1,2-ethanedisulfonic acid,
2-hydroxyethanesulfonic acid, benzenesulfonic acid,
2-naphthalenesulfonic acid, or naphthalenesulfonic acid.
Pharmaceutical salts can also be obtained by reacting a compound
with a base to form a salt such as an ammonium salt, an alkali
metal salt, such as a lithium, sodium or a potassium salt, an
alkaline earth metal salt, such as a calcium, magnesium or aluminum
salt, a salt of organic bases such as dicyclohexylamine,
N-methyl-D-glucamine, tris(hydroxymethyl)methylamine,
C.sub.1-C.sub.7 alkylamine, cyclohexylamine, dicyclohexylamine,
triethanolamine, ethylenediamine, ethanolamine, diethanolamine,
triethanolamine, tromethamine, and salts with amino acids such as
arginine and lysine; or a salt of an inorganic base, such as
aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium
carbonate, sodium hydroxide, or the like.
The term "solvate" as used herein is a broad term, and is to be
given its ordinary and customary meaning to a person of ordinary
skill in the art (and is not to be limited to a special or
customized meaning), and refers without limitation to mean that the
solvent is complexed with a compound in a reproducible molar ratio,
including, but not limited to, 0.5:1, 1:1, or 2:1. Thus, the term
"pharmaceutically acceptable solvate," refers to a solvate wherein
the solvent is one that does not cause significant irritation to an
organism to which it is administered and does not abrogate the
biological activity and properties of the compound.
The term "prodrug" as used herein is a broad term, and is to be
given its ordinary and customary meaning to a person of ordinary
skill in the art (and is not to be limited to a special or
customized meaning), and refers without limitation to a compound or
a pharmaceutical composition that can be administered to a patient
in a less active or inactive form, which can then be metabolized in
vivo into a more active metabolite. In certain embodiments, upon in
vivo administration, a prodrug is chemically converted to the
biologically, pharmaceutically, or therapeutically active form of
the compound. In certain embodiments, a prodrug is enzymatically
metabolized by one or more steps or processes to the biologically,
pharmaceutically, or therapeutically active form of the
compound.
It is understood that, in any compound described herein having one
or more chiral centers, if an absolute stereochemistry is not
expressly indicated, then each center may independently be of
R-configuration or S-configuration or a mixture thereof. Thus, the
compounds provided herein may be enantiomerically pure,
enantiomerically enriched, or may be stereoisomeric mixtures, and
include all diastereomeric, and enantiomeric forms. In addition it
is understood that, in any compound described herein having one or
more double bond(s) generating geometrical isomers that can be
defined as E or Z, each double bond may independently be E or Z a
mixture thereof. Stereoisomers are obtained, if desired, by methods
such as, stereoselective synthesis and/or the separation of
stereoisomers by chiral chromatographic columns. In some
embodiments, the compounds described herein (for example, compounds
of Formula (I) or Formula (II), and pharmaceutically acceptable
salts of any of the foregoing) are present in a racemic mixture. In
some embodiments, the compounds described herein (for example,
compounds of Formula (I) or Formula (II), and pharmaceutically
acceptable salts of any of the foregoing) are in the
S-configuration. In some embodiments, the compounds described
herein (for example, compounds of Formula (I) or Formula (II), and
pharmaceutically acceptable salts of any of the foregoing) are in
the R-configuration.
Likewise, it is understood that, in any compound described, all
tautomeric forms are also intended to be included.
Wherever a substituent is depicted as a di-radical (i.e., has two
points of attachment to the rest of the molecule), it is to be
understood that the substituent can be attached in any directional
configuration unless otherwise indicated. Thus, for example, a
substituent depicted as -AE- or
##STR00011## includes the substituent being oriented such that the
A is attached at the leftmost attachment point of the molecule as
well as the case in which A is attached at the rightmost attachment
point of the molecule.
It is to be understood that where compounds disclosed herein have
unfilled valencies, then the valencies are to be filled with
hydrogens and/or deuteriums.
It is understood that the compounds described herein can be labeled
isotopically or by another other means, including, but not limited
to, the use of chromophores or fluorescent moieties, bioluminescent
labels, or chemiluminescent labels. Substitution with isotopes such
as deuterium may afford certain therapeutic advantages resulting
from greater metabolic stability, such as, for example, increased
in vivo half-life or reduced dosage requirements. Each chemical
element as represented in a compound structure may include any
isotope of said element. For example, in a compound structure a
hydrogen atom may be explicitly disclosed or understood to be
present in the compound. At any position of the compound that a
hydrogen atom may be present, the hydrogen atom can be any isotope
of hydrogen, including but not limited to hydrogen-1 (protium),
hydrogen-2 (deuterium), and hydrogen-3 (tritium). Thus, reference
herein to a compound encompasses all potential isotopic forms
unless the context clearly dictates otherwise.
It is understood that the methods and formulations described herein
include the use of crystalline forms, amorphous phases, and/or
pharmaceutically acceptable salts, solvates, hydrates, and
conformers of compounds of preferred embodiments, as well as
metabolites and active metabolites of these compounds having the
same type of activity. A conformer is a structure that is a
conformational isomer. Conformational isomerism is the phenomenon
of molecules with the same structural formula but different
conformations (conformers) of atoms about a rotating bond. In
specific embodiments, the compounds described herein exist in
solvated forms with pharmaceutically acceptable solvents such as
water, ethanol, or the like. In other embodiments, the compounds
described herein exist in unsolvated form. Solvates contain either
stoichiometric or non-stoichiometric amounts of a solvent, and may
be formed during the process of crystallization with
pharmaceutically acceptable solvents such as water, ethanol, or the
like. Hydrates are formed when the solvent is water, or alcoholates
are formed when the solvent is alcohol. In addition, the compounds
provided herein can exist in unsolvated as well as solvated forms.
In general, the solvated forms are considered equivalent to the
unsolvated forms for the purposes of the compounds and methods
provided herein. Other forms in which the compounds of preferred
embodiments can be provided include amorphous forms, milled forms
and nano-particulate forms.
Likewise, it is understood that the compounds described herein,
such as compounds of preferred embodiments, include the compound in
any of the forms described herein (e.g., pharmaceutically
acceptable salts, prodrugs, crystalline forms, amorphous form,
solvated forms, enantiomeric forms, tautomeric forms, and the
like).
Some embodiments provide a compound of Formula (I), Formula (II),
or a pharmaceutically acceptable salt of any of the foregoing,
##STR00012##
In some embodiments, X and X.sub.1 are each independently CH.sub.2,
C.dbd.O, SO, SO.sub.2, or CH.sub.2CO. In some embodiments, X and
X.sub.1 are each independently CH.sub.2 or C.dbd.O. In some
embodiments, X and X.sub.1 are each CH.sub.2. In other embodiments,
X and X.sub.1 are each C.dbd.O. In still other embodiments, one of
X and X.sub.1 is C.dbd.O, and the other of X and X.sub.1 is
CH.sub.2.
In some embodiments, Y is H. In some embodiments, Y is deuterium.
In some embodiments, Y is halogen, for example, fluoro, chloro, or
bromo. In some embodiments, Y is an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl.
In some embodiments, R.sub.1 is --NH.sub.2, --NHR.sub.1A,
--NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C, --NR.sub.1AC(O)R.sub.1C,
--NHSO.sub.2R.sub.1C, or --NHR.sub.1ASO.sub.2R.sub.1C. In some
embodiments, R.sub.1 is --N[C(O)R.sub.1A][C(O)R.sub.1C].
In some embodiments, R.sub.1A, R.sub.1B, and R.sub.1C are
independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, or
an optionally substituted 5 to 10 membered heteroaryl.
In some embodiments, X and X.sub.1 are each C.dbd.O, R.sub.1 is
--NHR.sub.1A, and R.sub.1A is an optionally substituted
C.sub.1-C.sub.6 alkyl or an optionally substituted C.sub.3-C.sub.6
cycloalkyl.
In some embodiments, X and X.sub.1 are each C.dbd.O, R.sub.1 is
--NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently an
optionally substituted C.sub.1-C.sub.6 alkyl or an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, for example, methyl, ethyl,
n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl,
cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
In some embodiments, X and X.sub.1 are each C.dbd.O, R.sub.1 is
--NHC(O)R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.6-C.sub.10 aryl or an optionally substituted 5 to 10 membered
heteroaryl.
In some embodiments, X and X.sub.1 are each C.dbd.O, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, an
optionally substituted C.sub.6-C.sub.10 aryl, or an optionally
substituted 5 to 10 membered heteroaryl, for example, methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl,
phenyl, naphthyl, furan, pyrrole, imidazole, thiophene, pyridine,
or pyrimidine.
In some embodiments, X and X.sub.1 are each C.dbd.O, R.sub.1 is
--N[C(O)R.sub.1A][C(O)R.sub.1C], and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, an
optionally substituted C.sub.6-C.sub.10 aryl, or an optionally
substituted 5 to 10 membered heteroaryl, for example, methyl,
ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl,
phenyl, naphthyl, furan, pyrrole, imidazole, thiophene, pyridine,
or pyrimidine.
In some embodiments, R.sub.1 is hydroxy. In some embodiments,
R.sub.1 is halogen, for example, fluoro, chloro, or bromo. In some
embodiments, R.sub.1 is nitro. In some embodiments, R.sub.1 is
cyano. In some embodiments, R.sub.1 is optionally substituted
C.sub.1-C.sub.6 alkoxy. In some embodiments, R.sub.1 is --NH.sub.2.
In some embodiments, R.sub.1 is --NHR.sub.1A, --NR.sub.1AR.sub.1B,
--NHC(O)R.sub.1C, --NR.sub.1AC(O)R.sub.1C, --NHSO.sub.2R.sub.1C, or
--NR.sub.1ASO.sub.2R.sub.1C. In some embodiments, R.sub.1 is
--N[C(O)R.sub.1A][C(O)R.sub.1C]. In some embodiments, R.sub.1 is an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments, R.sub.1 is an optionally
substituted C.sub.1-C.sub.6 alkyl. In some embodiments, R.sub.1 is
an optionally substituted C.sub.3-C.sub.6 cycloalkyl. In some
embodiments, R.sub.1 is an optionally substituted 3 to 10 membered
heterocyclyl. In some embodiments, R.sub.1 is an optionally
substituted C.sub.6-C.sub.10 aryl. In some embodiments, R.sub.1 is
an optionally substituted 5 to 10 membered heteroaryl.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, or
an optionally substituted 5 to 10 membered heteroaryl.
In some embodiments, R.sub.2 is an unsubstituted C.sub.1-C.sub.6
alkyl, an unsubstituted C.sub.3-C.sub.6 cycloalkyl, an
unsubstituted 3 to 10 membered heterocyclyl, an unsubstituted
C.sub.6-C.sub.10 aryl, or an unsubstituted 5 to 10 membered
heteroaryl.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl. In some
embodiments, R.sub.2 is an optionally substituted C.sub.3-C.sub.6
cycloalkyl, for example, cyclopropyl, cyclobutyl, cyclopentyl, or
cyclohexyl.
In some embodiments, R.sub.3, R.sub.6, and R.sub.7 are
independently selected from a hydrogen, a deuterium, a halogen, an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.1-C.sub.6 alkoxy, an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, and an optionally substituted 5 to 10 membered
heteroaryl.
In some embodiments, R.sub.3, R.sub.6, and R.sub.7 are each
hydrogen. In some embodiments, one of R.sub.3, R.sub.6, and R.sub.7
is halogen, and the other two are hydrogen. In some embodiments,
one of R.sub.3, R.sub.6, and R.sub.7 is an optionally substituted
C.sub.1-C.sub.6 alkyl, and the other two are hydrogen. In some
embodiments, two of R.sub.3, R.sub.6, and R.sub.7 are halogen, and
the other one is hydrogen. In some embodiments, two of R.sub.3,
R.sub.6, and R.sub.7 are an optionally substituted C.sub.1-C.sub.6
alkyl, and the other one is hydrogen.
In some embodiments, R.sub.4 and R.sub.5 are independently selected
from an optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, and an optionally substituted 5 to 10
membered heteroaryl. In some embodiments, R.sub.4 and R.sub.5 are
independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, n-propyl,
isopropyl, n-butyl, isobutyl, sec-butyl, or t-butyl. In some
embodiments, R.sub.4 and R.sub.5 are independently an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, for example, cyclopropyl,
cyclobutyl, cyclopentyl, or cyclohexyl. In some embodiments, one of
R.sub.4 and R.sub.5 is an optionally substituted C.sub.1-C.sub.6
alkyl and the other is an optionally substituted C.sub.3-C.sub.6
cycloalkyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an optionally substituted 5 or 6
membered heterocyclyl, for example, an optionally substituted
dioxolane or an optionally substituted 1,4-dioxane. In some
embodiments, R.sub.4 and R.sub.5, together with the atoms to which
they are attached, form an unsubstituted dioxolane or an
unsubstituted 1,4-dioxane.
In some embodiments, when R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl, at least one of R.sub.4 and R.sub.5 is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, an optionally
substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, an optionally substituted 5 to
10 membered heteroaryl, or R.sub.4 and R.sub.5, together with the
atoms to which they are attached, form an optionally substituted 5
or 6 membered heterocyclyl. In some embodiments, when R.sub.2 is an
optionally substituted C.sub.1-C.sub.4 alkyl or NH(C.sub.1-C.sub.6
alkyl), at least one of R.sub.4 and R.sub.5 is an optionally
substituted cyclopropyl. In some embodiments, when R.sub.2 is an
optionally substituted C.sub.1-C.sub.6 alkyl, R.sub.4 and R.sub.5
are independently selected from an optionally substituted
C.sub.3-C.sub.6 cycloalkyl. In some embodiments, when R.sub.2 is an
optionally substituted C.sub.1-C.sub.6 alkyl, R.sub.4 is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl and R.sub.5 is an
optionally substituted C.sub.1-C.sub.6 alkyl. In some embodiments,
when R.sub.2 is an optionally substituted C.sub.1-C.sub.6 alkyl,
R.sub.5 is an optionally substituted C.sub.3-C.sub.6 cycloalkyl and
R.sub.4 is an optionally substituted C.sub.1-C.sub.6 alkyl. In some
embodiments, when R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an optionally substituted 5 or 6
membered heterocyclyl, for example, an optionally substituted
dioxolane or an optionally substituted 1,4-dioxane.
In some embodiments, when a C.sub.1-C.sub.6 alkyl, a
C.sub.1-C.sub.6 alkoxy, a C.sub.3-C.sub.6 cycloalkyl, a
C.sub.6-C.sub.10 aryl, a 3 to 10 membered heterocyclyl, or a 5 to
10 membered heteroaryl is substituted, the substituted substituents
are independently selected from a deuterium, an oxo, a halogen,
cyano, a nitro, an optionally substituted C.sub.1-C.sub.6 alkyl, an
optionally substituted C.sub.1-C.sub.6 haloalkyl, an optionally
substituted C.sub.1-C.sub.6 alkoxy, an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted
C.sub.6-C.sub.10 aryl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted 5 to 10 membered
heteroaryl, --C(O)R.sub.A, --C(O)OR.sub.A, --C(O)NR.sub.BR.sub.C,
--OR.sub.A, --OC(O)R.sub.A, --OC(O)NR.sub.BR.sub.C, --OS(O)R.sub.A,
--OS(O).sub.2R.sub.A, --OS(O)NR.sub.BR.sub.C,
--OS(O).sub.2NR.sub.BR.sub.C, --NR.sub.BR.sub.C,
--NR.sub.AC(O)R.sub.A, --NR.sub.AC(O)OR.sub.A,
--NR.sub.AC(O)NR.sub.BR.sub.C, --NR.sub.AS(O)R.sub.A,
--NR.sub.AS(O).sub.2R.sub.A, --NR.sub.AS(O)NR.sub.BR.sub.C,
--NR.sub.AS(O).sub.2NR.sub.BR.sub.C, --SR.sub.A, --S(O)R.sub.A,
--S(O).sub.2R.sub.A, --S(O)NR.sub.BR.sub.C, and
--S(O).sub.2NR.sub.BR.sub.C.
In some embodiments, each R.sub.A, R.sub.B, and R.sub.C are
independently selected from a hydrogen, an unsubstituted
C.sub.1-C.sub.6 alkyl, an unsubstituted C.sub.2-C.sub.6 alkenyl, an
unsubstituted C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10
membered heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, and
an unsubstituted 5 to 10 membered heteroaryl.
In some embodiments, R.sub.B and R.sub.C, together with the
nitrogen atom to which they are attached, form an optionally
substituted 3 to 10 membered heterocyclyl.
In some embodiments, one of X and X.sub.1 is CH.sub.2 and the other
is C.dbd.O. In some embodiments, X and X.sub.1 are each CH.sub.2.
In some embodiments, X and X.sub.1 are each C.dbd.O. In some
embodiments, one of X and X.sub.1 is CH.sub.2 and the other is SO.
In some embodiments, one of X and X.sub.1 is CH.sub.2 and the other
is SO.sub.2. In some embodiments, one of X and X.sub.1 is CH.sub.2
and the other is CH.sub.2CO. In some embodiments, one of X and
X.sub.1 is C.dbd.O and the other one of X and X.sub.1 is SO. In
some embodiments, one of X and X.sub.1 is C.dbd.O and the other one
of X and X.sub.1 is SO.sub.2. In some embodiments, one of X and
X.sub.1 is C.dbd.O and the other is CH.sub.2CO.
In some embodiments, R.sub.1 is --NHR.sub.1A, --NHC(O)R.sub.1C or
--NR.sub.1AC(O)R.sub.1C. In some embodiments, R.sub.1 is
--NHC(O)R.sub.1C. In some embodiments, R.sub.1 is
--N[C(O)R.sub.1A][C(O)R.sub.1C]. In some embodiments, R.sub.1A,
R.sub.1B, and R.sub.1C are independently an optionally substituted
C.sub.1-C.sub.6 alkyl or an optionally substituted C.sub.3-C.sub.6
cycloalkyl. In some embodiments, R.sub.1C is an optionally
substituted C.sub.1-C.sub.6 alkyl. In some embodiments, R.sub.1C is
an unsubstituted C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sub.3, R.sub.6, and R.sub.7 are
independently selected from a hydrogen, a halogen, and an
optionally substituted C.sub.1-C.sub.6 alkyl. In some embodiments,
R.sub.3, R.sub.6, and R.sub.7 are each hydrogen.
In some embodiments, R.sub.8 is hydrogen or deuterium. In some
embodiments, R.sub.8 is hydrogen. In other embodiments, R.sub.8 is
deuterium.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.1-C.sub.6 alkyl and one of R.sub.4 and R.sub.5 is an
optionally substituted C.sub.1-C.sub.6 alkyl and the other is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl or an optionally
substituted 3 to 10 membered heterocyclyl.
In some embodiments, R.sub.2 is an unsubstituted C.sub.1-C.sub.6
alkyl and one of R.sub.4 and R.sub.5 is an unsubstituted
C.sub.1-C.sub.6 alkyl and the other is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl or an optionally substituted 3 to 10
membered heterocyclyl.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, or an optionally substituted 5 to 10 membered heteroaryl, and
R.sub.4 and R.sub.5 are independently an optionally substituted
C.sub.1-C.sub.6 alkyl.
In some embodiments, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3 to 10
membered heterocyclyl, an optionally substituted C.sub.6-C.sub.10
aryl, or an optionally substituted 5 to 10 membered heteroaryl, and
R.sub.4 and R.sub.5 are independently unsubstituted C.sub.1-C.sub.6
alkyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an optionally substituted 5 or 6
membered heterocyclyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an unsubstituted 5 or 6 membered
heterocyclyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an unsubstituted 5 membered
heterocyclyl.
In some embodiments, R.sub.4 and R.sub.5, together with the atoms
to which they are attached, form an unsubstituted 6 membered
heterocyclyl.
In some embodiments, the compound of Formula (I) is selected
from:
##STR00013## ##STR00014## ##STR00015## ##STR00016## or a
pharmaceutically acceptable salt of any of the foregoing. In some
embodiments of this paragraph, X and X.sub.1 are each independently
CH.sub.2, C.dbd.O, SO, SO.sub.2, or CH.sub.2CO. In some embodiments
of this paragraph, X and X.sub.1 are each CH.sub.2. In some
embodiments of this paragraph, X and X.sub.1 are each C.dbd.O. In
some embodiments of this paragraph, X and X.sub.1 are each SO. In
some embodiments of this paragraph, X and X.sub.1 are each
SO.sub.2. In some embodiments of this paragraph, X and X.sub.1 are
each CH.sub.2CO. In some embodiments of this paragraph, one of X
and X.sub.1 is CH.sub.2 and the other of X and X.sub.1 is C.dbd.O.
In some embodiments of this paragraph, one of X and X.sub.1 is
CH.sub.2 and the other of X and X.sub.1 is SO. In some embodiments
of this paragraph, one of X and X.sub.1 is CH.sub.2 and the other
of X and X.sub.1 is SO.sub.2. In some embodiments of this
paragraph, one of X and X.sub.1 is CH.sub.2 and the other of X and
X.sub.1 is CH.sub.2CO. In some embodiments of this paragraph, one
of X and X.sub.1 is C.dbd.O and the other of X and X.sub.1 is SO.
In some embodiments of this paragraph, one of X and X.sub.1 is
C.dbd.O and the other of X and X.sub.1 is SO.sub.2. In some
embodiments of this paragraph, one of X and X.sub.1 is C.dbd.O and
the other of X and X.sub.1 is CH.sub.2CO. In some embodiments of
this paragraph, R.sub.2 is hydroxy, --NH.sub.2, --NHR.sub.1A,
--NR.sub.1AR.sub.1B, an optionally substituted C.sub.1-C.sub.6
alkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkyl, an
optionally substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, or an optionally substituted 5
to 10 membered heteroaryl. In some embodiments of this paragraph,
R.sub.2 is hydroxy. In some embodiments of this paragraph,
R.sub.2--NH.sub.2. In some embodiments of this paragraph, R.sub.2
is an optionally substituted C.sub.1-C.sub.6 alkyl, for example,
methyl, ethyl, propyl, isopropyl, butyl, sec-buty, t-butyl,
--CF.sub.3, --CH.sub.2F, --CF.sub.2H, --CD.sub.3,
--C(CH.sub.3).sub.2CF.sub.3, benzyl, or substituted benzyl In some
embodiments of this paragraph, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, for example, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.2 is an optionally substituted 3 to 10 membered heterocyclyl,
for example, oxetane, azetidine, pyrrolidine, tetrahydrofuran,
imidazoline, pyrazolidine, oxazolidine, isoxazolidine,
thiazolidine, isothiazolidine, dioxolane, piperidine,
tetrahydropyran, piperazine, morpholine, dioxane. In some
embodiments of this paragraph, R.sub.2 is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.2 is optionally substituted 5
to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1A and
R.sub.1B are independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, or
an optionally substituted 5 to 10 membered heteroaryl. In some
embodiments of this paragraph, R.sub.2 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.2 is --NHR.sub.1A, and R.sub.1A is an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.2 is --NHR.sub.1A, and R.sub.1A is an optionally substituted
3 to 10 membered heterocyclyl, for example, oxetane, azetidine,
pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.2 is
--NHR.sub.1A, and R.sub.1A is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.2 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted 5 to 10 membered heteroaryl,
for example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.2 is --NR.sub.1AR.sub.1B, and R.sub.1A and
R.sub.1B are independently an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, propyl,
isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted benzyl.
In some embodiments of this paragraph, R.sub.2 is
--NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.2 is --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.2 is --NR.sub.1AR.sub.1B,
and R.sub.1A and R.sub.1B are independently an optionally
substituted C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.2 is --NR.sub.1AR.sub.1B, and
R.sub.1A and R.sub.1B are independently an optionally substituted 5
to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.2 is
--NR.sub.1AR.sub.1B, one of R.sub.1A and R.sub.1B is an optionally
substituted C.sub.1-C.sub.6 alkyl and the other of R.sub.1A and
R.sub.1B is an optionally substituted C.sub.6-C.sub.10 aryl or an
optionally substituted 3 to 10 membered heterocyclyl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5 are
independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, and
an optionally substituted 5 to 10 membered heteroaryl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5, together with
the atoms to which they are attached, form an optionally
substituted 5 or 6 membered heterocyclyl. In some embodiments of
this paragraph, R.sub.4 and R.sub.5 are independently selected from
an optionally substituted C.sub.1-C.sub.6 alkyl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5 are
independently selected from an optionally substituted
C.sub.3-C.sub.6 cycloalkyl. In some embodiments of this paragraph,
R.sub.4 and R.sub.5 are independently selected from, an optionally
substituted 3 to 10 membered heterocyclyl. In some embodiments of
this paragraph, R.sub.4 and R.sub.5 are independently selected from
an optionally substituted C.sub.6-C.sub.10 aryl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5 are
independently selected from and an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph, one of
R.sub.4 and R.sub.5 is an optionally substituted C.sub.1-C.sub.6
alkyl and the other of R.sub.4 and R.sub.5 is an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph, one of
R.sub.4 and R.sub.5 is an optionally substituted C.sub.1-C.sub.6
alkyl and the other of R.sub.4 and R.sub.5 is an unsubstituted
C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10 membered
heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, or an
unsubstituted 5 to 10 membered heteroaryl. In some embodiments of
this paragraph, one of R.sub.4 and R.sub.5 is an unsubstituted
C.sub.1-C.sub.6 alkyl and the other of R.sub.4 and R.sub.5 is an
unsubstituted C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10
membered heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, or
an unsubstituted 5 to 10 membered heteroaryl. In some embodiments
of this paragraph, when R.sub.2 is an optionally substituted
C.sub.1-C.sub.4 alkyl or NH(C.sub.1-C.sub.6 alkyl), at least one of
R.sub.4 and R.sub.5 is an optionally substituted cyclopropyl, an
optionally substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, an optionally-substituted 5 to
10 membered heteroaryl, or R.sub.4 and R.sub.5, together with the
atoms to which they are attached, form an optionally substituted 5
or 6 membered heterocyclyl.
In some embodiments, the compound of Formula (II) is selected
from:
##STR00017## ##STR00018## ##STR00019## ##STR00020## ##STR00021## or
a pharmaceutically acceptable salt of any of the foregoing. In some
embodiments of this paragraph, X and X.sub.1 are each independently
CH.sub.2, C.dbd.O, SO, SO.sub.2, or CH.sub.2CO. In some embodiments
of this paragraph, X and X.sub.1 are each CH.sub.2. In some
embodiments of this paragraph, X and X.sub.1 are each C.dbd.O. In
some embodiments of this paragraph, X and X.sub.1 are each SO. In
some embodiments of this paragraph, X and X.sub.1 are each
SO.sub.2. In some embodiments of this paragraph, X and X.sub.1 are
each CH.sub.2CO. In some embodiments of this paragraph, one of X
and X.sub.1 is CH.sub.2 and the other of X and X.sub.1 is C.dbd.O.
In some embodiments of this paragraph, one of X and X.sub.1 is
CH.sub.2 and the other of X and X.sub.1 is SO. In some embodiments
of this paragraph, one of X and X.sub.1 is CH.sub.2 and the other
of X and X.sub.1 is SO.sub.2. In some embodiments of this
paragraph, one of X and X.sub.1 is CH.sub.2 and the other of X and
X.sub.1 is CH.sub.2CO. In some embodiments of this paragraph, one
of X and X.sub.1 is C.dbd.O and the other of X and X.sub.1 is SO.
In some embodiments of this paragraph, one of X and X.sub.1 is
C.dbd.O and the other of X and X.sub.1 is SO.sub.2. In some
embodiments of this paragraph, one of X and X.sub.1 is C.dbd.O and
the other of X and X.sub.1 is CH.sub.2CO. In some embodiments of
this paragraph, R.sub.2 is hydroxy, --NH.sub.2, --NHR.sub.1A,
--NR.sub.1AR.sub.1B, an optionally substituted C.sub.1-C.sub.6
alkyl, an optionally substituted C.sub.3-C.sub.6 cycloalkyl, an
optionally substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, or an optionally substituted 5
to 10 membered heteroaryl. In some embodiments of this paragraph,
R.sub.2 is hydroxy. In some embodiments of this paragraph,
R.sub.2--NH.sub.2. In some embodiments of this paragraph, R.sub.2
is an optionally substituted C.sub.1-C.sub.6 alkyl, for example,
methyl, ethyl, propyl, isopropyl, butyl, sec-buty, t-butyl,
--CF.sub.3, --CH.sub.2F, --CF.sub.2H, --CD.sub.3,
--C(CH.sub.3).sub.2CF.sub.3, benzyl, or substituted benzyl In some
embodiments of this paragraph, R.sub.2 is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, for example, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.2 is an optionally substituted 3 to 10 membered heterocyclyl,
for example, oxetane, azetidine, pyrrolidine, tetrahydrofuran,
imidazoline, pyrazolidine, oxazolidine, isoxazolidine,
thiazolidine, isothiazolidine, dioxolane, piperidine,
tetrahydropyran, piperazine, morpholine, dioxane. In some
embodiments of this paragraph, R.sub.2 is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.2 is optionally substituted 5
to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1A and
R.sub.1B are independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, or
an optionally substituted 5 to 10 membered heteroaryl. In some
embodiments of this paragraph, R.sub.2 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.2 is --NHR.sub.1A, and R.sub.1A is an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.2 is --NHR.sub.1A, and R.sub.1A is an optionally substituted
3 to 10 membered heterocyclyl, for example, oxetane, azetidine,
pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.2 is
--NHR.sub.1A, and R.sub.1A is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.2 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted 5 to 10 membered heteroaryl,
for example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.2 is --NR.sub.1AR.sub.1B, and R.sub.1A and
R.sub.1B are independently an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, propyl,
isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted benzyl.
In some embodiments of this paragraph, R.sub.2 is
--NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.2 is --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.2 is --NR.sub.1AR.sub.1B,
and R.sub.1A and R.sub.1B are independently an optionally
substituted C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.2 is --NR.sub.1AR.sub.1B, and
R.sub.1A and R.sub.1B are independently an optionally substituted 5
to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.2 is
--NR.sub.1AR.sub.1B, one of R.sub.1A and R.sub.1B is an optionally
substituted C.sub.1-C.sub.6 alkyl and the other of R.sub.1A and
R.sub.1B is an optionally substituted C.sub.6-C.sub.10 aryl or an
optionally substituted 3 to 10 membered heterocyclyl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5 are
independently selected from an optionally substituted
C.sub.1-C.sub.6 alkyl, an optionally substituted C.sub.3-C.sub.6
cycloalkyl, an optionally substituted 3 to 10 membered
heterocyclyl, an optionally substituted C.sub.6-C.sub.10 aryl, and
an optionally substituted 5 to 10 membered heteroaryl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5, together with
the atoms to which they are attached, form an optionally
substituted 5 or 6 membered heterocyclyl. In some embodiments of
this paragraph, R.sub.4 and R.sub.5 are independently selected from
an optionally substituted C.sub.1-C.sub.6 alkyl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5 are
independently selected from an optionally substituted
C.sub.3-C.sub.6 cycloalkyl. In some embodiments of this paragraph,
R.sub.4 and R.sub.5 are independently selected from, an optionally
substituted 3 to 10 membered heterocyclyl. In some embodiments of
this paragraph, R.sub.4 and R.sub.5 are independently selected from
an optionally substituted C.sub.6-C.sub.10 aryl. In some
embodiments of this paragraph, R.sub.4 and R.sub.5 are
independently selected from and an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph, one of
R.sub.4 and R.sub.5 is an optionally substituted C.sub.1-C.sub.6
alkyl and the other of R.sub.4 and R.sub.5 is an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph, one of
R.sub.4 and R.sub.5 is an optionally substituted C.sub.1-C.sub.6
alkyl and the other of R.sub.4 and R.sub.5 is an unsubstituted
C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10 membered
heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, or an
unsubstituted 5 to 10 membered heteroaryl. In some embodiments of
this paragraph, one of R.sub.4 and R.sub.5 is an unsubstituted
C.sub.1-C.sub.6 alkyl and the other of R.sub.4 and R.sub.5 is an
unsubstituted C.sub.3-C.sub.6 cycloalkyl, an unsubstituted 3 to 10
membered heterocyclyl, an unsubstituted C.sub.6-C.sub.10 aryl, or
an unsubstituted 5 to 10 membered heteroaryl. In some embodiments
of this paragraph, when R.sub.2 is an optionally substituted
C.sub.1-C.sub.4 alkyl or NH(C.sub.1-C.sub.6 alkyl), at least one of
R.sub.4 and R.sub.5 is an optionally substituted cyclopropyl, an
optionally substituted 3 to 10 membered heterocyclyl, an optionally
substituted C.sub.6-C.sub.10 aryl, an optionally-substituted 5 to
10 membered heteroaryl, or R.sub.4 and R.sub.5, together with the
atoms to which they are attached, form an optionally substituted 5
or 6 membered heterocyclyl.
In some embodiments, the compound of Formula (I) is selected
from:
##STR00022## ##STR00023## ##STR00024## or a pharmaceutically
acceptable salt of any of the foregoing. In some embodiments of
this paragraph, R.sub.1 is H, deuterium, hydroxy, halogen, nitro,
cyano, optionally substituted C.sub.1-C.sub.6 alkoxy, --NH.sub.2,
--NHR.sub.1A, --NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C,
--NR.sub.1AC(O)R.sub.1C, --NHSO.sub.2R.sub.1C,
--NR.sub.1ASO.sub.2R.sub.1C, --N[C(O)R.sub.1A][C(O)R.sub.1C]. an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph,
R.sub.1A, R.sub.1B, and R.sub.1C are independently selected from an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph, R.sub.1
is H. In some embodiments of this paragraph, R.sub.1 is hydroxy. In
some embodiments of this paragraph, R.sub.1 is nitro. In some
embodiments of this paragraph, R.sub.1 is cyano. In some
embodiments of this paragraph, R.sub.1 is halogen, for example,
fluoro, chloro, or bromo. In some embodiments of this paragraph,
R.sub.1 is optionally substituted C.sub.1-C.sub.6 alkoxy, for
example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy,
t-butoxy, --OCF.sub.3, or --OCD.sub.3. In some embodiments of this
paragraph, R.sub.1 is an optionally substituted C.sub.1-C.sub.6
alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl,
sec-buty, t-butyl, --CF.sub.3, --CH.sub.2F, --CF.sub.2H,
--CD.sub.3, --C(CH.sub.3).sub.2CF.sub.3, benzyl, or substituted
benzyl In some embodiments of this paragraph, R.sub.1 is
--NH.sub.2. In some embodiments of this paragraph, R.sub.1 is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, for example,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In some
embodiments of this paragraph, R.sub.1 is an optionally substituted
3 to 10 membered heterocyclyl, for example, oxetane, azetidine,
pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.1 is an
optionally substituted C.sub.6-C.sub.10 aryl, for example,
substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is optionally substituted 5 to 10 membered heteroaryl, for
example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.1 is --NHR.sub.1A, and R.sub.1A is an optionally
substituted C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl,
propyl, isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted
benzyl. In some embodiments of this paragraph, R.sub.1 is
--NHR.sub.1A, and R.sub.1A is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted C.sub.6-C.sub.10 aryl, for
example, substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NHR.sub.1A, and R.sub.1A is an optionally substituted
5 to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently an
optionally substituted C.sub.1-C.sub.6 alkyl, for example, methyl,
ethyl, propyl, isopropyl, butyl, sec-buty, t-butyl, benzyl, or
substituted benzyl. In some embodiments of this paragraph, R.sub.1
is --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently
an optionally substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.1 is --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is --NR.sub.1AR.sub.1B,
and R.sub.1A and R.sub.1B are independently an optionally
substituted C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.1 is --NR.sub.1AR.sub.1B, and
R.sub.1A and R.sub.1B are independently an optionally substituted 5
to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AR.sub.1B, one of R.sub.1A and R.sub.1B is an optionally
substituted C.sub.1-C.sub.6 alkyl and the other of R.sub.1A and
R.sub.1B is an optionally substituted C.sub.6-C.sub.10 aryl or an
optionally substituted 3 to 10 membered heterocyclyl. In some
embodiments of this paragraph, R.sub.1 is --NHC(O)R.sub.1C, and
R.sub.1C is an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.1 is --NHC(O)R.sub.1C, and R.sub.1C is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.1 is --NHC(O)R.sub.1C, and R.sub.1C is an optionally
substituted 3 to 10 membered heterocyclyl, for example, oxetane,
azetidine, pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.1 is
--NHC(O)R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.1 is --NHC(O)R.sub.1C, and
R.sub.1C is an optionally substituted 5 to 10 membered heteroaryl,
for example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.1 is --NHSO.sub.2R.sub.1C, and R.sub.1C is an
optionally substituted C.sub.1-C.sub.6 alkyl, for example, methyl,
ethyl, propyl, isopropyl, butyl, sec-buty, t-butyl, benzyl, or
substituted benzyl. In some embodiments of this paragraph, R.sub.1
is --NHSO.sub.2R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is
--N[C(O)R.sub.1A][C(O)R.sub.1C], and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.1 is --NHSO.sub.2R.sub.1C, and R.sub.1C is an
optionally substituted 3 to 10 membered heterocyclyl, for example,
oxetane, azetidine, pyrrolidine, tetrahydrofuran, imidazoline,
pyrazolidine, oxazolidine, isoxazolidine, thiazolidine,
isothiazolidine, dioxolane, piperidine, tetrahydropyran,
piperazine, morpholine, dioxane. In some embodiments of this
paragraph, R.sub.1 is --NHSO.sub.2R.sub.1C, and R.sub.1C is an
optionally substituted C.sub.6-C.sub.10 aryl, for example,
substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NHSO.sub.2R.sub.1C, and R.sub.1C is an optionally
substituted 5 to 10 membered heteroaryl, for example, substituted
or unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.1 is --NR.sub.1AC(O)R.sub.1C, and R.sub.1A and
R.sub.1C are independently an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.6-C.sub.10 aryl, for
example, substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted 5 to 10 membered
heteroaryl, for example, substituted or unsubstituted furan,
furazan, pyrrole, oxazole, benzoxazole, imidazole, benzimidazole,
indole, indazole, pyrazole, benzopyrazole, isoxazole,
benzoisoxazole, triazole, benzotriazole, thiadiazole, tetrazole,
pyridine, pyridazine, pyrimidine, pyrazine, quinoline,
isoquinoline, quinazoline, quinoxaline, cinnoline, or triazine. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, one of R.sub.1A and R.sub.1C is an
optionally substituted C.sub.1-C.sub.6 alkyl and the other of
R.sub.1A and R.sub.1C is an optionally substituted C.sub.6-C.sub.10
aryl or an optionally substituted 3 to 10 membered heterocyclyl. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.1 is --NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and
R.sub.1C are independently an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.6-C.sub.10 aryl, for
example, substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C
are independently an optionally substituted 5 to 10 membered
heteroaryl, for example, substituted or unsubstituted furan,
furazan, pyrrole, oxazole, benzoxazole, imidazole, benzimidazole,
indole, indazole, pyrazole, benzopyrazole, isoxazole,
benzoisoxazole, triazole, benzotriazole, thiadiazole, tetrazole,
pyridine, pyridazine, pyrimidine, pyrazine, quinoline,
isoquinoline, quinazoline, quinoxaline, cinnoline, or triazine. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, one of R.sub.1A and R.sub.1C is an
optionally substituted C.sub.1-C.sub.6 alkyl and the other of
R.sub.1A and R.sub.1C is an optionally substituted C.sub.6-C.sub.10
aryl or an optionally substituted 3 to 10 membered
heterocyclyl.
In some embodiments, the compound of Formula (II) is selected
from:
##STR00025## ##STR00026## ##STR00027## or a pharmaceutically
acceptable salt of any of the foregoing. In some embodiments of
this paragraph, R.sub.1 is H, deuterium, hydroxy, halogen, nitro,
cyano, optionally substituted C.sub.1-C.sub.6 alkoxy, --NH.sub.2,
--NHR.sub.1A, --NR.sub.1AR.sub.1B, --NHC(O)R.sub.1C,
--NR.sub.1AC(O)R.sub.1C, --NHSO.sub.2R.sub.1C,
--NR.sub.1ASO.sub.2R.sub.1C, --N[C(O)R.sub.1A][C(O)R.sub.1C], an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph,
R.sub.1A, R.sub.1B, and R.sub.1C are independently selected from an
optionally substituted C.sub.1-C.sub.6 alkyl, an optionally
substituted C.sub.3-C.sub.6 cycloalkyl, an optionally substituted 3
to 10 membered heterocyclyl, an optionally substituted
C.sub.6-C.sub.10 aryl, or an optionally substituted 5 to 10
membered heteroaryl. In some embodiments of this paragraph, R.sub.1
is H. In some embodiments of this paragraph, R.sub.1 is hydroxy. In
some embodiments of this paragraph, R.sub.1 is nitro. In some
embodiments of this paragraph, R.sub.1 is cyano. In some
embodiments of this paragraph, R.sub.1 is halogen, for example,
fluoro, chloro, or bromo. In some embodiments of this paragraph,
R.sub.1 is optionally substituted C.sub.1-C.sub.6 alkoxy, for
example, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy,
t-butoxy, --OCF.sub.3, or --OCD.sub.3. In some embodiments of this
paragraph, R.sub.1 is an optionally substituted C.sub.1-C.sub.6
alkyl, for example, methyl, ethyl, propyl, isopropyl, butyl,
sec-buty, t-butyl, --CF.sub.3, --CH.sub.2F, --CF.sub.2H,
--CD.sub.3, --C(CH.sub.3).sub.2CF.sub.3, benzyl, or substituted
benzyl In some embodiments of this paragraph, R.sub.1 is
--NH.sub.2. In some embodiments of this paragraph, R.sub.1 is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, for example,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In some
embodiments of this paragraph, R.sub.1 is an optionally substituted
3 to 10 membered heterocyclyl, for example, oxetane, azetidine,
pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.1 is an
optionally substituted C.sub.6-C.sub.10 aryl, for example,
substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is optionally substituted 5 to 10 membered heteroaryl, for
example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.1 is --NHR.sub.1A, and R.sub.1A is an optionally
substituted C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl,
propyl, isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted
benzyl. In some embodiments of this paragraph, R.sub.1 is
--NHR.sub.1A, and R.sub.1A is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is --NHR.sub.1A, and
R.sub.1A is an optionally substituted C.sub.6-C.sub.10 aryl, for
example, substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NHR.sub.1A, and R.sub.1A is an optionally substituted
5 to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently an
optionally substituted C.sub.1-C.sub.6 alkyl, for example, methyl,
ethyl, propyl, isopropyl, butyl, sec-buty, t-butyl, benzyl, or
substituted benzyl. In some embodiments of this paragraph, R.sub.1
is --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are independently
an optionally substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.1 is --NR.sub.1AR.sub.1B, and R.sub.1A and R.sub.1B are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is --NR.sub.1AR.sub.1B,
and R.sub.1A and R.sub.1B are independently an optionally
substituted C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.1 is --NR.sub.1AR.sub.1B, and
R.sub.1A and R.sub.1B are independently an optionally substituted 5
to 10 membered heteroaryl, for example, substituted or
unsubstituted furan, furazan, pyrrole, oxazole, benzoxazole,
imidazole, benzimidazole, indole, indazole, pyrazole,
benzopyrazole, isoxazole, benzoisoxazole, triazole, benzotriazole,
thiadiazole, tetrazole, pyridine, pyridazine, pyrimidine, pyrazine,
quinoline, isoquinoline, quinazoline, quinoxaline, cinnoline, or
triazine. In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AR.sub.1B, one of R.sub.1A and R.sub.1B is an optionally
substituted C.sub.1-C.sub.6 alkyl and the other of R.sub.1A and
R.sub.1B is an optionally substituted C.sub.6-C.sub.10 aryl or an
optionally substituted 3 to 10 membered heterocyclyl. In some
embodiments of this paragraph, R.sub.1 is --NHC(O)R.sub.1C, and
R.sub.1C is an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.1 is --NHC(O)R.sub.1C, and R.sub.1C is an
optionally substituted C.sub.3-C.sub.6 cycloalkyl, cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, 2,2-difluorocyclopropyl, or
2,2-difluorocyclobutyl. In some embodiments of this paragraph,
R.sub.1 is --NHC(O)R.sub.1C, and R.sub.1C is an optionally
substituted 3 to 10 membered heterocyclyl, for example, oxetane,
azetidine, pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.1 is
--NHC(O)R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.1 is --NHC(O)R.sub.1C, and
R.sub.1C is an optionally substituted 5 to 10 membered heteroaryl,
for example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.1 is --N[C(O)R.sub.1A][C(O)R.sub.1C], and R.sub.1A
and R.sub.1C are independently an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, propyl,
isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted benzyl.
In some embodiments of this paragraph, R.sub.1 is
--NHSO.sub.2R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, propyl,
isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted benzyl.
In some embodiments of this paragraph, R.sub.1 is
--NHSO.sub.2R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is
--NHSO.sub.2R.sub.1C, and R.sub.1C is an optionally substituted 3
to 10 membered heterocyclyl, for example, oxetane, azetidine,
pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.1 is
--NHSO.sub.2R.sub.1C, and R.sub.1C is an optionally substituted
C.sub.6-C.sub.10 aryl, for example, substituted phenyl,
unsubstituted phenyl, naphthyl, or unsubstituted naphthyl. In some
embodiments of this paragraph, R.sub.1 is --NHSO.sub.2R.sub.1C, and
R.sub.1C is an optionally substituted 5 to 10 membered heteroaryl,
for example, substituted or unsubstituted furan, furazan, pyrrole,
oxazole, benzoxazole, imidazole, benzimidazole, indole, indazole,
pyrazole, benzopyrazole, isoxazole, benzoisoxazole, triazole,
benzotriazole, thiadiazole, tetrazole, pyridine, pyridazine,
pyrimidine, pyrazine, quinoline, isoquinoline, quinazoline,
quinoxaline, cinnoline, or triazine. In some embodiments of this
paragraph, R.sub.1 is --NR.sub.1AC(O)R.sub.1C, and R.sub.1A and
R.sub.1C are independently an optionally substituted
C.sub.1-C.sub.6 alkyl, for example, methyl, ethyl, propyl,
isopropyl, butyl, sec-buty, t-butyl, benzyl, or substituted benzyl.
In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.3-C.sub.6 cycloalkyl,
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In some
embodiments of this paragraph, R.sub.1 is --NR.sub.1AC(O)R.sub.1C,
and R.sub.1A and R.sub.1C are independently an optionally
substituted 3 to 10 membered heterocyclyl, for example, oxetane,
azetidine, pyrrolidine, tetrahydrofuran, imidazoline, pyrazolidine,
oxazolidine, isoxazolidine, thiazolidine, isothiazolidine,
dioxolane, piperidine, tetrahydropyran, piperazine, morpholine,
dioxane. In some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.6-C.sub.10 aryl, for
example, substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NR.sub.1AC(O)R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted 5 to 10 membered
heteroaryl, for example, substituted or unsubstituted furan,
furazan, pyrrole, oxazole, benzoxazole, imidazole, benzimidazole,
indole, indazole, pyrazole, benzopyrazole, isoxazole,
benzoisoxazole, triazole, benzotriazole, thiadiazole, tetrazole,
pyridine, pyridazine, pyrimidine, pyrazine, quinoline,
isoquinoline, quinazoline, quinoxaline, cinnoline, or triazine. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1AC(O)R.sub.1C, one of R.sub.1A and R.sub.1C is an
optionally substituted C.sub.1-C.sub.6 alkyl and the other of
R.sub.1A and R.sub.1C is an optionally substituted C.sub.6-C.sub.10
aryl or an optionally substituted 3 to 10 membered heterocyclyl. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.1-C.sub.6 alkyl, for
example, methyl, ethyl, propyl, isopropyl, butyl, sec-buty,
t-butyl, benzyl, or substituted benzyl. In some embodiments of this
paragraph, R.sub.1 is --NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and
R.sub.1C are independently an optionally substituted
C.sub.3-C.sub.6 cycloalkyl, cyclopropyl, cyclobutyl, cyclopentyl,
cyclohexyl, 2,2-difluorocyclopropyl, or 2,2-difluorocyclobutyl. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted 3 to 10 membered
heterocyclyl, for example, oxetane, azetidine, pyrrolidine,
tetrahydrofuran, imidazoline, pyrazolidine, oxazolidine,
isoxazolidine, thiazolidine, isothiazolidine, dioxolane,
piperidine, tetrahydropyran, piperazine, morpholine, dioxane. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C are
independently an optionally substituted C.sub.6-C.sub.10 aryl, for
example, substituted phenyl, unsubstituted phenyl, naphthyl, or
unsubstituted naphthyl. In some embodiments of this paragraph,
R.sub.1 is --NR.sub.1ASO.sub.2R.sub.1C, and R.sub.1A and R.sub.1C
are independently an optionally substituted 5 to 10 membered
heteroaryl, for example, substituted or unsubstituted furan,
furazan, pyrrole, oxazole, benzoxazole, imidazole, benzimidazole,
indole, indazole, pyrazole, benzopyrazole, isoxazole,
benzoisoxazole, triazole, benzotriazole, thiadiazole, tetrazole,
pyridine, pyridazine, pyrimidine, pyrazine, quinoline,
isoquinoline, quinazoline, quinoxaline, cinnoline, or triazine. In
some embodiments of this paragraph, R.sub.1 is
--NR.sub.1ASO.sub.2R.sub.1C, one of R.sub.1A and R.sub.1C is an
optionally substituted C.sub.1-C.sub.6 alkyl and the other of
R.sub.1A and R.sub.1C is an optionally substituted C.sub.6-C.sub.10
aryl or an optionally substituted 3 to 10 membered
heterocyclyl.
In some embodiments, the compound is a pharmaceutically acceptable
salt.
One or more of the compounds of preferred embodiments can be
provided in the form of pharmaceutically acceptable salts,
solvates, active metabolites, tautomers, or prodrugs thereof. Some
embodiments can be provided in pharmaceutical compositions
comprising a therapeutically effective amount of the compound. In
some embodiments, the pharmaceutical composition also contains at
least one pharmaceutically acceptable inactive ingredient. The
pharmaceutical composition can be formulated for intravenous
injection, subcutaneous injection, oral administration, buccal
administration, inhalation, nasal administration, topical
administration, transdermal administration, ophthalmic
administration, or optic administration. The pharmaceutical
composition can be in the form of a tablet, a pill, a capsule, a
liquid, an inhalant, a nasal spray solution, a suppository, a
suspension, a gel, a colloid, a dispersion, a solution, an
emulsion, an ointment, a lotion, an eye drop, or an ear drop.
In some embodiments, the pharmaceutical composition is formulated
as a gel, salve, ointment, cream, emulsion, or paste for topical
application to the skin.
The pharmaceutical compositions of preferred embodiments can
further comprise one or more additional therapeutically active
agents other than a compound of the preferred embodiments. Such
agents can include, but are not limited to, anti-inflammatory
agents, anti-cancer agents, immunostimulatory agents, and
immunosuppressive agents.
Some embodiments provide a method of treating, ameliorating, or
preventing a disease, disorder, or condition associated with PDE4,
comprising administering a therapeutically effective amount of a
compound of any one of Formula (I), Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing, or a
composition comprising any one of Formula (I) or Formula (II) to a
subject in need thereof.
In some embodiments, the disease, disorder, or condition is
selected from the group consisting of arthritis, ankylosing
spondylitis, osteoarthritis, rheumatoid arthritis, Behcet's
disease, inflammatory bowel diseases (e.g., Crohn's disease and
ulcerative colitis), psoriasis, psoriatic arthritis, atopic
dermatitis, contact dermatitis, and combinations thereof. In some
embodiments, the disease, disorder, or condition is arthritis. In
some embodiments, the disease, disorder, or condition is ankylosing
spondylitis. In some embodiments, the disease, disorder, or
condition is osteoarthritis. In some embodiments, the disease,
disorder, or condition is rheumatoid arthritis. In some
embodiments, the disease, disorder, or condition is Behcet's
disease. In some embodiments, the disease, disorder, or condition
is Crohn's disease. In some embodiments, the disease, disorder, or
condition is ulcerative colitis. In some embodiments, the disease,
disorder, or condition is psoriasis. In some embodiments, the
disease, disorder, or condition is psoriatic arthritis. In some
embodiments, the disease, disorder, or condition is atopic
dermatitis. In some embodiments, the disease, disorder, or
condition is contact dermatitis. In some embodiments, the disease,
disorder, or condition is selected from two of arthritis,
ankylosing spondylitis, osteoarthritis, rheumatoid arthritis,
Behcet's disease, inflammatory bowel diseases (e.g., Crohn's
disease and ulcerative colitis), psoriasis, psoriatic arthritis,
atopic dermatitis, and contact dermatitis.
In some embodiments, the compound or composition is administered in
combination with a second therapeutic agent. In some embodiments,
the second therapeutic agent is selected from the group consisting
of anti-inflammatory agents, anti-cancer agents, immunostimulatory
agents, and immunosuppressive agents. In some embodiments, the
second therapeutic agent is an anti-inflammatory agent or an
immunosuppressive agent.
Some embodiments provide a method of decreasing expression of a
protein selected from TNF-.alpha., INF-.gamma., IL-2, IL-17, IL-23,
or a combination thereof, comprising contacting a cell with a
compound of any one of Formula (I) or Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing. In some
embodiments, the protein is TNF-.alpha.. Some embodiments provide a
method of decreasing expression of TNF-.alpha.. Some embodiments
provide a method of decreasing expression of INF-.gamma.. Some
embodiments provide a method of decreasing expression of IL-2. Some
embodiments provide a method of decreasing expression of IL-17.
Some embodiments provide a method of decreasing expression of
IL-23. Some embodiments provide a method of decreasing expression
of two proteins selected from TNF-.alpha., INF-.gamma., IL-2,
IL-17, and IL-23. Some embodiments provide a method of decreasing
expression of three proteins selected from TNF-.alpha.,
INF-.gamma., IL-2, IL-17, and IL-23. Some embodiments provide a
method of decreasing expression of four proteins selected from
TNF-.alpha., INF-.gamma., IL-2, IL-17, and IL-23. Some embodiments
provide a method of decreasing expression of TNF-.alpha.,
INF-.gamma., IL-2, IL-17, and IL-23.
In some embodiments, protein expression is decreased by about 10%
to about 90%, about 5% to about 25%, about 20% to about 40%, about
35% to about 55%, about 50% to about 75%, about 70% to about 90%,
or any value in between. In some embodiments, protein expression is
decreased by about 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%,
15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%,
28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%,
41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%,
54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%,
67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%,
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, 99%, or any value in between.
Some embodiments provide a method of inhibiting PDE4 activity,
comprising contacting a cell with a compound of any one of Formula
(I) or Formula (II), or a pharmaceutically acceptable salt of any
of the foregoing. In some embodiments, PDE4 activity is decreased
by about 10% to about 90%, about 5% to about 25%, about 20% to
about 40%, about 35% to about 55%, about 50% to about 75%, about
70% to about 90%, or any value in between. In some embodiments,
protein expression is decreased by about 5%, 6%, 7%, 8%, 9%, 10%,
11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%,
24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%,
37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%,
50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%,
63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 74%,
75%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,
89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or any value
in between.
Some embodiments provide a method of treating psoriasis, comprising
topically administering a therapeutically effective amount of a
composition comprising any one of Formula (I) or Formula (II), or a
pharmaceutically acceptable salt of any of the foregoing, to a
subject in need thereof.
In some embodiments, the subject is known to possess wild-type
PDE4. In some embodiments, the subject is known to possess
wild-type TNF-.alpha.. In some embodiments, the subject is known to
possess wild-type INF-.gamma., IL-2, IL-17, or IL-23. In some
embodiments, the subject is known to possess aberrant PDE4. In some
embodiments, the subject is known to possess aberrant TNF-.alpha..
In some embodiments, the subject is known to possess aberrant
INF-.gamma., IL-2, IL-17, or IL-23.
In some embodiments, the cell is known to possess wild-type PDE4.
In some embodiments, the cell is known to possess wild-type
TNF-.alpha.. In some embodiments, the cell is known to possess
wild-type INF-.gamma., IL-2, IL-17, or IL-23. In some embodiments,
the cell is known to possess aberrant PDE4. In some embodiments,
the cell is known to possess aberrant TNF-.alpha.. In some
embodiments, the cell is known to possess aberrant INF-.gamma.,
IL-2, IL-17, or IL-23.
Other objects, features, and advantages of the compounds, methods,
and compositions described herein will become apparent from the
following detailed description. It should be understood, however,
that the detailed description and the specific examples, while
indicating specific embodiments, are given by way of illustration
only, since various changes and modifications within the spirit and
scope of the instant disclosure will become apparent to those
skilled in the art from this detailed description.
Additional Therapeutic Agents
Some embodiments provide pharmaceutical compositions comprising a
compound of Formula (I) or Formula (II), and a pharmaceutically
acceptable carrier. Some embodiments provide pharmaceutical
compositions comprising of Formula (I) or Formula (II) a
pharmaceutically acceptable carrier, and a second therapeutic
agent.
In some embodiments, the second therapeutic agent is
anti-inflammatory agent. In some embodiments, the second
therapeutic agent is a non-steroidal anti-inflammatory agent. In
some embodiments, the second therapeutic agent is anti-cancer
agent. In some embodiments, the second therapeutic agent is an
immunostimulatory agent. In some embodiments, the second
therapeutic agent is an immunosuppressive agent. In some
embodiments, the second therapeutic agent is antibody.
In some embodiments, the second therapeutic agent is selected from
aspirin; diflunisal; salsalate; acetaminophen; ibuprofen;
dexibuprofen; naproxen; fenoprofen; ketoprofen; dexketoprofen;
flurbiprofen; oxaprozin; loxoprofen; indomethacin; tolmetin;
sulindac; etodolac; ketorolac; diclofenac; aceclofenac; nabumetone;
enolic acid; piroxicam; meloxicam; tenoxicam; droxicam; lornoxicam;
isoxicam; mefenamic acid; meclofenamic acid; flufenamic acid;
tolfenamic acid; sulfonanilides; clonixin; licofelone;
dexamethasone; and prednisone.
In some embodiments, the second therapeutic agent is selected from
mechlorethamine; cyclophosphamide; melphalan; chlorambucil;
ifosfamide; busulfan; N-nitroso-N-methylurea (MNU); carmustine
(BCNU); lomustine (CCNU); semustine (MeCCNU); fotemustine;
streptozotocin; dacarbazine; mitozolomide; temozolomide; thiotepa;
mytomycin; diaziquone (AZQ); cisplatin; carboplatin; and
oxaliplatin.
In some embodiments, the second therapeutic agent is selected from
vincristine; vinblastine; vinorelbine; vindesine; vinflunine;
paclitaxel; docetaxel; etoposide; teniposide; tofacitinib;
ixabepilone; irinotecan; topotecan; camptothecin; doxorubicin;
mitoxantrone; and teniposide.
In some embodiments, the second therapeutic agent is selected from
actinomycin; bleomycin; plicamycin; mitomycin; daunorubicin;
epirubicin; idarubicin; pirarubicin; aclarubicin; mitoxantrone;
cyclophosphamide; methotrexate; 5-fluorouracil; prednisolone;
folinic acid; methotrexate; melphalan; capecitabine;
mechlorethamine; uramustine; melphalan; chlorambucil; ifosfamide;
bendamustine; 6-mercaptopurine; and procarbazine.
In some embodiments, the second therapeutic agent is selected from
cladribine; pemetrexed; fludarabine; gemcitabine; hydroxyurea;
nelarabine; cladribine; clofarabine; ytarabine; decitabine;
cytarabine; cytarabine liposomal; pralatrexate; floxuridine;
fludarabine; colchicine; thioguanine; cabazitaxel; larotaxel;
ortataxel; tesetaxel; aminopterin; pemetrexed; pralatrexate;
raltitrexed; pemetrexed; carmofur; and floxuridine.
In some embodiments, the second therapeutic agent is selected from
azacitidine; decitabine; hydroxycarbamide; topotecan; irinotecan;
belotecan; teniposide; aclarubicin; epirubicin; idarubicin;
amrubicin; pirarubicin; valrubicin; zorubicin; mitoxantrone;
pixantrone; mechlorethamine; chlorambucil; prednimustine;
uramustine; estramustine; carmustine; lomustine; fotemustine;
nimustine; ranimustine; carboquone; thioTEPA; triaziquone; and
triethylenemelamine.
In some embodiments, the second therapeutic agent is selected from
nedaplatin; satraplatin; procarbazine; dacarbazine; temozolomide;
altretamine; mitobronitol; pipobroman; actinomycin; bleomycin;
plicamycin; aminolevulinic acid; methyl aminolevulinate;
efaproxiral; talaporfin; temoporfin; verteporfin; alvocidib;
seliciclib; palbociclib; bortezomib; carfilzomib; anagrelide;
masoprocol; olaparib; belinostat; panobinostat; romidepsin;
vorinosta; idelalisib; atrasentan; bexarotene; testolactone;
amsacrine; trabectedin; alitretinoin; tretinoin; demecolcine;
elsamitrucin; etoglucid; lonidamine; lucanthone; mitoguazone;
mitotane; oblimersen; omacetaxine mepesuccinate; and eribulin.
In some embodiments, the second therapeutic agent is selected from
azathioprine; Mycophenolic acid; leflunomide; teriflunomide;
tacrolimus; cyclosporin; pimecrolimus; abetimus; gusperimus;
lenalidomide; pomalidomide; thalidomide; anakinra; sirolimus;
everolimus; ridaforolimus; temsirolimus; umirolimus; zotarolimus;
eculizumab; adalimumab; afelimomab; certolizumab pegol; golimumab;
infliximab; nerelimomab; mepolizumab; omalizumab; faralimomab;
elsilimomab; lebrikizumab; ustekinumab; etanercept; otelixizumab;
teplizumab; visilizumab; clenoliximab; keliximab; zanolimumab;
efalizumab; erlizumab; obinutuzumab; rituximab; and
ocrelizumab.
In some embodiments, the second therapeutic agent is selected from
pascolizumab; gomiliximab; lumiliximab; teneliximab; toralizumab;
aselizumab; galiximab; gavilimomab; ruplizumab; belimumab;
blisibimod; ipilimumab; tremelimumab; bertilimumab; lerdelimumab;
metelimumab; natalizumab; tocilizumab; odulimomab; basiliximab;
daclizumab; inolimomab; zolimoma; atorolimumab; cedelizumab;
fontolizumab; maslimomab; morolimumab; pexelizumab; reslizumab;
rovelizumab; siplizumab; talizumab; telimomab; vapaliximab;
vepalimomab; abatacept; belatacept; pegsunercept; aflibercept;
alefacept; and rilonacept.
Dosing Regimes
In some embodiments, about 1 mg to about 5 grams; 2 mg to 2 gram; 5
mg to about 1 gram; 10 mg to about 800 mg; 20 mg to 600 mg; 30 mg
to 400 mg; 40 mg to 200 mg; 50 mg to 100 mg of a compound of
Formula (I), Formula (II), or any amount in between, is
administered each day. In some embodiments, about 1 mg to about 5
grams; 2 mg to 2 gram; 5 mg to about 1 gram; 10 mg to about 800 mg;
20 mg to 600 mg; 30 mg to 400 mg; 40 mg to 200 mg; 50 mg to 100 mg
of a compound of Formula (I), Formula (II), or any amount in
between, is administered each week. In some embodiments, about 1 mg
to about 5 grams; 2 mg to 2 gram; 5 mg to about 1 gram; 10 mg to
about 800 mg; 20 mg to 600 mg; 30 mg to 400 mg; 40 mg to 200 mg; 50
mg to 100 mg of a compound of Formula (I), Formula (II), or any
amount in between, is administered each cycle of treatment.
In some embodiments, a compound of Formula (I) or Formula (II) is
administered at least once per day, at least twice per day, at
least three times per day, or at least four times per day. In some
embodiments, a compound of Formula (I) or Formula (II) is
administered at least once per day, at least twice per day, at
least three times per day, or at least four times per week. In some
embodiments, each cycle of treatment lasts 1, 2, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12, 13, or 14 days, or any value in between. In some
embodiments, each cycle of treatment has at least 1, 2, 3, 4, 5, 6,
or 7 days between administrations of a compound of Formula (I),
Formula (II), or any value in between.
In some embodiments, a compound of Formula (I) or Formula (II) is
provided intravenously over about 10, 20, 30, 40, 50, 60, 90, 120,
150, 180, 210, or 240 minutes, or any value in between.
EXAMPLES
Additional embodiments are disclosed in further detail in the
following examples, which are not in any way intended to limit the
scope of the claims.
Characterization of the compounds disclosed herein was performed
with Bruker AV-500 and Bruker DRX-500 NMR spectrometers and a
Perkin Elmer PE-SCIEX API-150 mass spectrometer.
Synthesis
##STR00028##
##STR00029##
##STR00030##
Example 1: Compound 1:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-diox-
o-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
##STR00031##
A solution of
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (40 mg, 0.094 mmol) in pyridine
(4 mL) was cooled to 0.degree. C. then acetyl chloride (0.15 mL in
1 mL DCM) was added. The mixture was stirred at 0.degree. C. for
0.5 h. HCl (2 M, 3 mL) was added and the organic layer was
separated, washed with brine, dried over Na.sub.2SO.sub.4,
concentrated, and purified on silica gel (ethyl acetate
(EA)/petroleum ether (PE) 40%-70%) to give the title compound (25.0
mg, 57%) as a white solid. MS (ESI) m/z 467.0 [M+H].sup.+. .sup.1H
NMR (400 MHz, CDCl.sub.3) .delta. 9.42 (s, 1H), 7.23 (s, 1H),
7.00-6.98 (m, 2H), 6.74 (d, J=8.0 Hz, 1H), 5.76-5.73 (m, 1H),
4.52-4.45 (m, 1H), 4.04-3.99 (m, 2H), 3.77 (s, 3H), 3.70-3.66 (m,
1H), 2.80 (s, 3H), 2.21 (s, 3H), 1.40-1.36 (m, 3H).
Example 2: Compound 2:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-diox-
o-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)pivalamide
##STR00032##
To a solution of
(S)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (400 mg, 0.88
mmol) in THF (10 mL) was added Pd/C (200 mg). The mixture stirred
at RT under hydrogen overnight, then filtered, concentrated, and
purified on silica gel to give
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c] pyrrole-4,6(5H)-dione (281 mg, 75%) as a yellow
solid.
To a solution of
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (100 mg, 0.236 mmol) in pyridine
(5 mL) was added pivaloyl chloride (56 mg, 0.47 mmol) at 0.degree.
C. The mixture was stirred at RT for 4 h, diluted with water then
extracted with EA. The combined organic layers were washed with HCl
(1N), dried over Na.sub.2SO.sub.4, filtered, concentrated, and
purified on silica gel eluting with EA/PE from 40% to 70% to give
the title compound (21.0 mg, 17.5%) as a white solid. MS (ESI)
m/z=509.1 [M+H].sup.+. .sup.1H NMR (DMSO-d6, 400 MHz) .delta. 11.52
(s, 1H), 7.81 (s, 1H), 7.04 (s, 1H), 6.93 (s, 2H), 5.74 (d, J=8.8
Hz, 1H), 4.40-4.33 (m, 1H), 4.09 (d, J=12.0 Hz, 1H), 4.01 (d, J=6.8
Hz, 2H), 3.73 (s, 3H), 3.02 (s, 3H), 1.36-1.21 (m, 12H).
Example 3: Compound 3:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-diox-
o-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-methoxyacetamide
##STR00033##
To a cooled (0.degree. C.) solution of
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (40 mg, 0.094 mmol) in pyridine
(3 mL) was added 2-methoxyacetyl chloride (0.1 mL in 1 mL DCM). The
mixture was stirred at 0.degree. C. for 0.5 h. HCl (2M, 3 mL) was
added and the organic layer was washed with brine, dried over
Na.sub.2SO.sub.4, concentrated and purified on silica gel eluting
with EA/PE from 40% to 70% to give the title compound (15 mg, 32%)
as a white solid. MS (ESI) m/z 497.1 [M+H].sup.+. .sup.1H NMR (400
MHz, CDCl.sub.3) .delta. 9.77 (s, 1H), 7.36 (s, 1H), 7.10-7.08 (m,
2H), 6.83 (d, J=8.8 Hz, 1H), 5.81 (dd, J=4.8 Hz, 10.4 Hz, 1H),
4.56-4.50 (m, 1H), 4.14-4.08 (m, 4H), 3.85 (s, 3H), 3.73 (dd, J=3.6
Hz, 14.4 Hz, 1H), 3.55 (s, 3H), 2.85 (s, 3H), 1.47 (t, J=6.8 Hz,
3H).
Example 4: Compound 4:
(S)--N-(cyclopropanecarbonyl)-N-(5-(1-(3-ethoxy-4-hydroxy
phenyl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]py-
rrol-1-yl)cyclopropanecarboxamide
##STR00034##
To a solution of
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (200 mg, 0.472 mmol) in pyridine
(5 mL) was added cyclopropanecarbonyl chloride (171 mg, 1.416 mmol)
at 0.degree. C., and the mixture was stirred at RT overnight. The
mixture was concentrated, diluted with water and extracted with EA.
The combined organic layers were washed with HCl (1N) and dried
over Na.sub.2SO.sub.4, filtered, concentrated, and purified by
prep-TLC (PE/EA, 1:1) to give the title compound (60.7 mg, 61.4%)
as a yellow solid. MS (ESI) m/z=578.2 [M+H.sub.2O].sup.+. .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 7.94 (s, 1H), 7.05 (s, 1H),
6.96-6.90 (m, 2H), 5.70 (dd, J=9.6, 4.4 Hz, 1H), 4.33-4.26 (m, 1H),
4.14-4.08 (m, 1H), 4.04-3.98 (m, 2H), 3.74 (s, 3H), 2.99 (s, 3H),
2.20-2.17 (m, 1H), 2.06-2.03 (m, 1H), 1.32 (t, J=7.2 Hz, 3H),
1.23-1.20 (m, 2H), 1.09-1.04 (m, 4H), 0.98 (s, 2H).
Example 5: Compound 5:
N-(5-((S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-
-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-3,3,3-trifluoro-2-methylpropanam-
ide
##STR00035##
To a solution of 3,3,3-trifluoro-2-methylpropanoic acid (34 mg,
0.24 mmol) in DMF (3 mL) was added 1-hydroxybenzotriazole (HOBt)
(48 mg, 0.354 mmol) and
3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine
hydrochloride (EDCI) (68 mg, 0.35 mmol), followed by DIEA (91 mg,
0.71 mmol).
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethy-
l)-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (100 mg, 0.236 mmol) was
added and the solution was stirred at RT for 16 h, concentrated and
purified on silica gel eluting with EA/PE from 40% to 70% to give
the title compound (14.5 mg, 11%) as a white solid. MS (ESI) m/z
547.1 [M-H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 12.22 (s,
1H), 7.86 (s, 1H), 7.04 (s, 1H), 6.93 (s, 2H), 5.71 ((dd, J=4.0 Hz,
10.0 Hz, 1H), 4.35-4.28 (m, 1H), 4.13-4.09 (m, 2H), 4.02-3.97 (m,
2H), 3.73 (s, 3H), 3.01 (s, 3H), 1.37-1.30 (m, 6H).
Example 6: Compound 6:
S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-
-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2-ethylbutanamide
##STR00036##
To a cooled (0 C) solution of
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (100 mg, 0.236 mmol) in pyridine
(3 mL) was added 2-ethylbutanoyl chloride (0.15 mL in 1 mL DCM).
After the mixture was stirred at 0 C for 0.5 h, HCl (2M, 3 mL) was
added. The organic layer was washed with brine, dried over
Na.sub.2SO.sub.4, concentrated, and purified on silica gel eluting
with EA/PE from 40% to 70% to give the title compound (25.3 mg,
20%) as a white solid. MS (ESI) m/z 523.2 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 11.75 (s, 1H), 7.78 (s, 1H), 7.04 (s,
1H), 6.93 (s, 2H), 5.71 ((dd, J=4.4 Hz, 10.4 Hz, 1H), 4.36-4.29 (m,
1H), 4.11 ((dd, J=4.4 Hz, 14.8 Hz, 1H), 4.02-3.97 (m, 2H), 3.73 (s,
3H), 3.01 (s, 3H), 2.78-2.74 (m, 1H), 1.59-1.43 (m, 4H), 1.34-1.30
(m, 3H), 0.83-0.80 (m, 6H).
Example 7: Compound 7:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-diox-
o-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2,2,2-trifluoroacetamide
##STR00037##
A solution of thiophene-3,4-dicarboxylic acid (25.0 g, 145 mmol) in
acetic anhydride (250 mL) was heated to 110.degree. C. for 16 h.
The mixture was then concentrated to give
thieno[3,4-c]furan-1,3-dione (22.0 g crude) as a yellow solid and
used for the next step without further purification.
Thieno[3,4-c]furan-1,3-dione (22.0 g, 143 mmol) was added to nitric
acid (95%, 90 mL) at 0-5.degree. C. over 1 h. The mixture was
warmed to RT for 1 h then poured into ice water and extracted with
EA. The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated to give 2-nitrothiophene-3,4-dicarboxylic
acid (20.8 g, 66%) as a yellow solid and used for the next step
without further purification.
A solution of 2-nitrothiophene-3,4-dicarboxylic acid (6.0 g, 27.6
mmol) in Ac.sub.2O (60 mL) was heated to 140.degree. C. for 3 h.
The mixture was concentrated to give
4-nitrothieno[3,4-c]furan-1,3-dione (5.5 g) as a yellow solid and
used for the next step without further purification.
A mixture of 4-nitrothieno[3,4-c]furan-1,3-dione (5.5 g, 27.64
mmol), and
(S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine (7.54
g, 27.64 mmol) in THF (250 mL) was stirred at RT for 16 h. Then
1,1'-carbonyldiimidazol (CDI) (5.37 g, 33.1 mmol) was added and the
reaction was heated to reflux for 3 h. The mixture was concentrated
and purified on silica gel eluting with EA/PE from 30% to 50% to
give
(S)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1-nitro-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (10.0 g, 79%) as a yellow
solid.
A mixture of (S)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (1.0 g, 2.2
mmol), NH.sub.4Cl (706 mg, 13.2 mmol) and iron powder (740 mg, 13.2
mmol) in THF/water (50 mL/10 mL) was heated to reflux for 1 h. The
reaction was filtered, concentrated, and to purified on silica gel
eluting with EA/PE from 40% to 70% to give
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c] pyrrole-4,6(5H)-dione (300 mg, 32%) as a yellow solid.
MS (ESI) m/z 424.9 [M+H].sup.+.
To a solution of
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (150 mg, 0.354 mmol) in ACN (3
mL) was added pyridine (1 mL). The mixture was cooled to 0.degree.
C., then trifluoroacetic anhydride (0.2 mL in 1 mL ACN) was added
at 0.degree. C. for 0.5 h. HCl (2M, 3 mL) was added. The organic
layer was washed with brine, dried over Na.sub.2SO.sub.4,
concentrated and purified on silica gel eluting with EA/PE from 40%
to 70% to give the title compound (30 mg, 16%) as a white solid. MS
(ESI) m/z 538.1 [M+H.sub.2O].sup.+. .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 7.81 (s, 1H), 7.09 (s, 1H), 6.98 (s, 2H), 5.76-5.73 (m,
1H), 4.43-4.36 (m, 1H), 4.15-4.10 (m, 1H), 4.07-4.03 (m, 2H), 3.78
(s, 3H), 3.06 (s, 3H), 1.39-1.36 (m, 3H).
Example 8: Compound 8:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-diox-
o-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)cyclopropanecarboxamide
##STR00038##
To a solution of cyclopropanecarboxylic acid (41 mg, 0.472 mmol) in
DMF (5 mL) was added HOBt (95 mg, 0.71 mmol) and EDCI (136 mg, 0.71
mmol) followed by DIEA (183 mg, 1.5 mmol).
(S)-1-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (200 mg, 0.472 mmol) was added
and the solution was stirred at RT for 16 h. The mixture was
concentrated and purified on silica gel eluting with EA/PE from 40%
to 70% to give the title compound (14 mg, 6%) as a yellow solid. MS
(ESI) m/z 493.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta.
12.01 (s, 1H), 7.76 (s, 1H), 7.06 (s, 1H), 6.95 (s, 2H), 5.74-5.71
(m, 1H), 4.35-4.31 (m, 1H), 4.14-4.09 (m, 1H), 4.04-3.99 (m, 2H),
3.74 (s, 3H), 3.02 (s, 3H), 2.52-2.51 (m, 1H), 1.35-1.31 (m, 3H),
0.96-0.90 (m, 4H).
Example 9: Compound 9:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4,6-diox-
o-5,6-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)-2,2,2-trifluoroacetamide
##STR00039##
To a solution of 4-bromothiophene-3-carboxylic acid (10.0 g, 48.35
mmol) in THF (100 mL) at RT was added hexamethylphosphoramide (1.75
g, 9.67 mmol). The mixture was cooled to -70.degree. C. and lithium
diisopropylamide (53 mL, 106.5 mmol, 2M in THF) was added under
N.sub.2. The reaction was stirred at this temperature for 1 h then
CO.sub.2 was bubbled for 30 min at -40.degree. C. The reaction was
warmed to RT and stirred for 15 min. The reaction was quenched with
water (100 mL) and adjusted to pH=10 with 10% NaOH (aq.). The
mixture was extracted with EA and the aqueous layer was adjusted to
pH=3 with 1 N HCl, extracted with EA, dried over Na.sub.2SO.sub.4,
filtered, concentrated, and washed with EA to give
4-bromothiophene-2,3-dicarboxylic acid (5.6 g, 46.2%) as a red
solid.
4-Bromothiophene-2,3-dicarboxylic acid (1.0 g, 4 mmol) was
dissolved in acetic anhydride (10 mL), and the suspension was
stirred at 135.degree. C. for 16 h. The solvent was removed and the
residue was dried to give 3-bromothieno[2,3-c]furan-4,6-dione (1.0
g, crude) as a brown solid which was used directly for the next
step.
To a solution of 3-bromothieno[2,3-c]furan-4,6-dione (900 mg, 3.88
mmol) in THF (15 mL) at RT was added
(S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine (1.06
g, 3.88 mmol), and the mixture was stirred for 1 h. Then
1,1'-carbonyldiimidazole (754.9 mg, 4.66 mol) was added and the
mixture was heated at 70.degree. C. for 3 h. The reaction was
concentrated and the residue was purified on silica gel eluting
with EA/PE from 10% to 50% to give
(S)-3-bromo-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth-
yl)-4H-thieno[2,3-c]pyrrole-4,6(5H)-dione (5) (1.52 g, 80%) as a
yellow solid. MS (ESI) m/z 504.9, 506.9 [M+H.sub.2O].sup.+.
To a suspension of
(S)-3-bromo-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrole-4,6(5H)-dione (500 mg, 1.03 mmol) in
1,4-dioxane/toluene (13 mL/13 mL) at RT was added
diphenylmethanimine (223.4 mg, 1.23 mmol) and cesium carbonate
(669.5 mg, 2.06 mmol). The suspension was degassed and purged with
nitrogen twice. Then tris(dibenzylideneacetone)dipalladium
(Pd.sub.2(dba).sub.3) (188.6 mg, 0.206 mmol) and Xantphos (178.8
mg, 0.309 mmol) was added. The suspension was heated at 100.degree.
C. for 16 h. The mixture was cooled to RT and concentrated. The
residue was purified on silica gel eluting with EA/PE from 10% to
50% to give (S)-3-((diphenyl
methylene)amino)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-
-4H-thieno[2,3-c]pyrrole-4,6(5H)-dione (241 mg, 39.8%) as a yellow
solid. MS (ESI) m/z 589.1 [M+H].sup.+.
To a solution of
(S)-3-((diphenylmethylene)amino)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methy-
lsulfonyl)ethyl)-4H-thieno[2,3-c]pyrrole-4,6(5H)-dione (240 mg,
0.408 mmol) in MeOH (10 mL) at RT was added NH.sub.2OH.HCl (113.4
mg, 1.632 mmol) and NaOAc (167 mg, 2.04 mmol). The suspension was
stirred at RT for 5 h then concentrated. The residue was purified
on silica gel eluting with EA/PE from 10% to 50% to give
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrole-4,6(5H)-dione (83 mg, 48%) as a yellow gum. MS
(ESI) m/z 424.9 [M+H].sup.+.
To a solution of
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrole-4,6(5H)-dione (83 mg, 0.196 mmol) in
DCM/pyridine (2 mL/2 mL) at 0.degree. C. was added the solution of
trifluoroacetic anhydride (123 mg, 0.587 mmol) in DCM (0.5 mL). The
reaction was stirred at 0.degree. C. for 10 min, quenched with
water (1 mL) and extracted with DCM. The combined organic layers
were washed with 1N HCl, dried over Na.sub.2SO.sub.4, filtered,
concentrated, and purified by prep-TLC (PE/EA, 1:1) to give the
title compound (54.5 mg, 53.5%) as a yellow solid. MS (ESI) m/z
521.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 11.71 (s,
1H), 8.18 (s, 1H), 7.05 (s, 1H), 6.95 (s, 2H), 5.67 (dd, J=4.0,
10.4 Hz, 1H), 4.29 (dd, J=10.0, 14.0 Hz, 1H), 4.10 (dd, J=4.4, 14.0
Hz, 1H), 4.01 (q, J=7.2 Hz, 2H), 3.74 (s, 3H), 3.00 (s, 3H), 1.32
(t, J=6.8 Hz, 3H).
Example 10: Compound 10:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)-2-methoxyacetam-
ide
##STR00040##
To a solution of
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrole-4,6(5H)-dione (73 mg, 0.172 mmol) in
DCM/pyridine (2 mL/2 mL) at 0.degree. C. was added the solution of
2-methoxyacetyl chloride (37 mg, 0.344 mmol) in DCM (0.5 mL). The
reaction was stirred at 0.degree. C. for 10 min and quenched with
water (1 mL) then extracted with DCM. The combined organic layers
were washed with 1 N HCl, dried over Na.sub.2SO.sub.4, filtered,
concentrated, and purified by prep-TLC (PE/EA, 1:1) to give the
title compound (30.3 mg, 35.6%) as a light yellow solid. MS (ESI)
m/z 497.1 [M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.55
(s, 1H), 8.31 (s, 1H), 7.04 (d, J=1.6 Hz, 1H), 6.98-6.92 (m, 2H),
5.67 (dd, J=4.0, 10.4 Hz, 1H), 4.28 (dd, J=11.2, 14.4 Hz, 1H), 4.10
(dd, J=4.4, 14.0 Hz, 1H), 4.09 (s, 2H), 4.01 (q, J=6.8 Hz, 2H),
3.74 (s, 3H), 3.41 (s, 3H), 3.01 (s, 3H), 1.32 (t, J=6.8 Hz,
3H).
Example 11: Compound 11:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)cyclopropanecarb-
oxamide
##STR00041##
To a solution of cyclopropanecarboxylic acid (533 mg, 6.19 mmol) in
DCM (5 mL) at 0.degree. C. was added a solution of oxalyl chloride
(1.17 g, 9.28 mmol) in DCM (1 mL). The reaction was stirred at
20.degree. C. for 3 h then concentrated to give
cyclopropanecarbonyl chloride (500 mg, crude) as a yellow oil. To a
solution of
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrole-4,6(5H)-dione (37 mg, 0.087 mmol) in
DCM/pyridine (2 mL/2 mL) at 0.degree. C. was added a solution of
cyclopropanecarbonyl chloride (10.5 mg, 0.131 mmol) in DCM (0.5
mL). The reaction was stirred at 0.degree. C. for 10 minutes,
quenched with water (1 mL) and extracted with DCM. The combined
organic layers were washed with 1 N HCl, dried over
Na.sub.2SO.sub.4, filtered, concentrated, and purified by prep-TLC
(PE/EA, 1:1.5) to give the title compound (46.9 mg, 64%) as a light
yellow solid. MS (ESI) m/z 493.1, 510.1 [M+H, M+H2O].sup.+. .sup.1H
NMR (400 MHz, DMSO-d6) .delta. 10.36 (s, 1H), 8.26 (s, 1H), 7.06
(s, 1H), 6.99-6.924 (m, 2H), 5.71 (dd, J=4.0, 10.4 Hz, 1H), 4.30
(dd, J=11.2, 14.4 Hz, 1H), 4.11 (dd, J=4.4, 14.4 Hz, 1H), 4.02 (q,
J=6.8 Hz, 2H), 3.75 (s, 3H), 3.03 (s, 3H), 2.09 (t, J=6.0 Hz, 1H),
1.33 (t, J=6.8 Hz, 3H), 0.83 (d, J=6.4 Hz, 2H).
Example 12: Compound 12 (S) and Compound 18 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-
-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
##STR00042##
To a solution of
(S)-1-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (130 mg, 0.33 mmol) in ACN (3 mL)
was added pyridine (0.1 mL). The mixture was cooled to 0.degree. C.
then acetyl chloride (0.1 mL in 1 mL ACN) was added dropwise, and
the mixture was stirred at 0.degree. C. for 0.5 h. HCl (2M, 3 mL)
was added, and the organic layer was washed with brine, dried over
Na.sub.2SO.sub.4, concentrated, and purified by prep-HPLC
(ACN/H.sub.2O, 5%-95%) to give Compound 12 (49 mg, 34%) as a white
solid. MS (ESI) m/z 437.1 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 11.73 (s, 1H), 7.75 (s, 1H), 7.06 (s, 1H), 6.89
(s, 2H), 6.02 (d, J=4.0, 2H), 5.69 (q, 1H), 4.31 (q, 1H), 4.08 (q,
1H), 3.01 (s, 3H), 2.23 (s, 1H). Compound 18 was prepared
analogously to Compound 12. MS (ESI) m/z 454.0
[M+H.sub.2O].sup.+.
Example 13: Compound 13 (S) and Compound 19 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-
-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)cyclopropane carboxamide
##STR00043##
To a solution of
(S)-1-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (180 mg, 0.46 mmol) in ACN (3 mL)
was added pyridine (0.1 mL). The mixture was cooled to 0.degree.
C., then cyclopropanecarbonyl chloride (0.3 mL in 1 mL ACN, which
was prepared from cyclopropanecarboxylic acid with SOCl.sub.2
reflux for 2H) was added drop wised, the mixture was stirred at
0.degree. C. for 0.5 h. HCl (2M, 3 mL) was added, the organic layer
was washed with brine, dried over Na.sub.2SO.sub.4, concentrated
and purified by prep-HPLC (ACN/H.sub.2O=5%-95%) to give the title
compound (48 mg, 23%) as a white solid. MS (ESI) m/z 463.8
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 11.98 (s, 1H),
7.75 (s, 1H), 7.07 (s, 1H), 6.90 (s, 2H), 6.02 (d, J=4.0, 2H), 5.70
(q, 1H), 4.31 (q, 1H), 4.08 (q, 1H), 3.01 (s, 3H), 2.31 (m, 1H),
0.92 (m, 4H). Compound 19 was prepared analogously to Compound 13.
MS (ESI) m/z 463.8 [M+H].sup.+.
Example 14: Compound 14 (S) and Compound 20 (R):
N-(5-(1-(2,3-dihydrobenzo[b][1,4]
dioxin-6-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-dihydro-4H-thieno[3,4-
-c]pyrrol-1-yl) acetamide
##STR00044##
A solution of 2,3-dihydrobenzo[b][1,4]dioxine-6-carbaldehyde (10.0
g, 60.97 mmol) in DMF (100 mL) was added dimethyl sulfone (11.0 g,
121.95 mmol) and NaOH (3.7 g, 91.46 mmol). The mixture was heated
to 50.degree. C. for 2 h, then concentrated and purified on silica
gel eluting with EA/PE from 50% to 80% to give
(E)-6-(2-(methylsulfonyl)vinyl)-2,3-dihydrobenzo[b][1,4]dioxine
(5.3 g, 36%) as a yellow solid. MS (ESI) m/z 241.2 [M+1].sup.+.
A mixture of
(E)-6-(2-(methylsulfonyl)vinyl)-2,3-dihydrobenzo[b][1,4]dioxine
(5.3 g, 22.08 mmol) and hydroxylamine (7.3 g, 221.2 mmol) in THF
(50 mL) was heated to reflux overnight. The mixture was
concentrated and purified on silica gel eluting with EA/PE from 80%
to 100% to give
N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)ethyl)hydrox-
ylamine (3.8 g, 62%) as a colorless oil. MS (ESI) m/z 275.1
[M+1].sup.+.
A mixture of
N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)ethyl)hydrox-
ylamine (3.8 g, 13.90 mmol) and Pd/C (380 mg) in MeOH (30 mL) was
stirred at RT under hydrogen overnight. The mixture was filtered
and the filtrate was concentrated to give crude
1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)ethanamine.
Chiral prep-HPLC afforded the two enantiomers: S isomer (peak 1,
320 mg) as a white solid and R isomer (peak 2, 350 mg) as a white
solid. S isomer MS (ESI) m/z 258.3 [M+1].sup.+.
A mixture of 4-nitrothieno[3,4-c]furan-1,3-dione (199 mg, 1.0 mmol)
and
(S)-1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)ethanamine
(257 mg, 1.0 mmol) in THF (15 mL) was stirred at RT for 1 h.
1,1'-Carbonyldiimidazol (195 mg, 1.2 mmol) was added and the
mixture was stirred at 80 C for 1 h. The mixture was diluted with
EA (100 mL), washed with water (100 mL) and brine (50 mL), dried
over Na.sub.2SO.sub.4, concentrated, and purified on silica gel
eluting with EA/PE (1:1) to give
(S)-5-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)ethyl)-1-
-nitro-4H-thieno[3, 4-c]pyrrole-4,6(5H)-dione(7) (300 mg, 68%) as a
yellow solid. MS (ESI) m/z 439.1 [M+1].sup.+.
A mixture of
(S)-5-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)ethyl)-1-
-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (150 mg, 0.34 mmol),
ammonium chloride (91 mg, 1.7 mmol) and iron powder (96 mg, 1.7
mmol) in THF/water (10 mL/3 mL) was stirred at 80.degree. C. for 1
h. The reaction was diluted with EA (100 mL), washed with water
(100 mL) and brine (50 mL), dried over Na.sub.2SO.sub.4,
concentrated, and purified on silica gel eluting with EA/PE (2:1)
to give
(S)-1-amino-5-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)-
ethyl)-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (21 mg, 15%) as a
yellow solid. MS (ESI) m/z 409.1 [M+H].sup.+.
To a solution of
(S)-1-amino-5-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-(methylsulfonyl)-
ethyl)-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (21 mg, 0.05 mmol) in
pyridine (4 mL) was added acetyl chloride (0.1 mL) at 0.degree. C.
The mixture was stirred at 0.degree. C. for 2 h. The reaction was
quenched with water (50 mL) and extracted with EA (50 mL). The
organic phase was washed with 0.5 N HCl (20 mL) and brine (50 mL).
The organic phase was dried over Na.sub.2SO.sub.4, concentrated,
and purified by prep-HPLC (ACN/H.sub.2O, 5%-95%) to give the title
compound (10.5 mg, 47%) as a white solid. MS (ESI) m/z 451.0
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.27 (s,
1H), 7.32 (s, 1H), 7.05 (d, J=2.0 Hz, 1H), 6.97 (dd, J=2.0, 8.4 Hz,
1H), 6.84 (d, J=8.4 Hz, 1H), 5.80 (dd, J=4.0, 10.4 Hz, 1H), 4.55
(dd, J=10.4, 14.4 Hz, 1H), 4.23 (s, 4H), 3.70 (dd, J=4.0, 14.4 Hz,
1H), 2.90 (s, 3H), 2.28 (s, 3H). Compound 20 was prepared
analogously to Compound 14. MS (ESI) m/z 468.0
[M+H.sub.2O].sup.+.
Example 15: Compound 15:
(S)--N-(5-(2-(N,N-dimethylsulfamoyl)-1-(3-ethoxy-4-methoxyphenyl)ethyl)-4-
,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
##STR00045##
To a solution of N,N-dimethylmethanesulfonamide (23.9 g, 194.23
mmol) in N,N-dimethylacetamide (150 mL) was added KOH (6.54 g,
116.55 mmol) at RT. The mixture was stirred for 15 min at RT. Then
3-ethoxy-4-methoxybenzaldehyde (14 g, 77.7 mmol) was added and the
mixture was stirred for 2 h at 60.degree. C. The mixture was poured
onto ice water (300 mL) and filtered, and purified on silica gel to
afford
(E)-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylethenesulfonamide (9.5
g, 43%) a white solid. MS (ESI) m/z=286.1 [M+H].sup.+.
To a solution of
(E)-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylethenesulfonamide (7.3
g, 25.56 mmol) in THF (70 mL) was added hydroxylamine (60 mL, 2.2
mol) at RT. The mixture was warmed to 60.degree. C. and stirred for
16 h. The mixture was poured onto ice water (50 mL) and stirred for
10 minutes then extracted with EA. The combined organic layers were
washed with brine, dried over Na.sub.2SO.sub.4, filtered, and
evaporated. The mixture was concentrated and purified on silica gel
to afford
2-(3-ethoxy-4-methoxyphenyl)-2-(hydroxyamino)-N,N-dimethylethanesulfonami-
de (4.5 g, 55%) a white solid. MS (ESI) m/z=319.0 [M+H].sup.+.
To a solution of
2-(3-ethoxy-4-methoxyphenyl)-2-(hydroxyamino)-N,N-dimethylethanesulfonami-
de (4.5 g, 14.13 mmol) in MeOH (50 mL) at RT was added Pd/C (1 g).
The mixture was stirred at RT overnight under hydrogen. The
suspension was filtered through a pad of celite and the filtrate
was concentrated. The residue was purified on silica gel to afford
2-amino-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylethanesulfonamide
(3.8 g, 89%) a white solid. Chiral Prep-HPLC gave two enantiomers:
S isomer (peak 1, 1.5 g) as a white solid and R isomer (peak 2, 1.4
g) as a white solid. S isomer MS (ESI) m/z=303.1 [M+H].sup.+.
.sup.1H NMR (400 MHz, DMSO-d6) .delta. 7.02 (s, 1H), 6.91-6.85 (m,
1H), 4.28-4.24 (m, 1H), 4.04-3.97 (m, 2H), 3.72 (m, 3H), 3.29-3.21
(m, 1H), 3.15-3.09 (m, 1H), 2.74-2.69 (m, 6H), 2.08 (m, 2H),
1.34-1.30 (m, 3H).
A mixture of 4-nitrothieno[3,4-c]furan-1,3-dione (199 mg, 1.0 mmol)
and
(S)-2-amino-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethylethanesulfonamide
(302 mg, 1.0 mmol) in THF (10 mL) was stirred at RT for 1 h.
1,1'-Carbonyldiimidazol (211 mg, 1.3 mmol) was added and the
mixture was stirred at 80.degree. C. for 1 h. The reaction was
diluted with EA (100 mL), washed with water (100 mL) and brine (50
mL), dried, concentrated, and purified on silica gel (PE/EA, 2:3)
to give
(S)-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethyl-2-(1-nitro-4,6-dioxo-4H-thi-
eno[3,4-c]pyrrol-5(6H)-yl)ethanesulfonamide (415 mg, 86%) as a
yellow solid. MS (ESI) m/z 484.1 [M+1].sup.+.
A mixture of
(S)-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethyl-2-(1-nitro-4,6-dioxo-4H-thi-
eno[3,4-c]pyrrol-5(6H)-yl)ethanesulfonamide (410 mg, 0.85 mmol),
ammonium chloride (228 mg, 4.25 mmol) and iron powder (238 mg, 4.25
mmol) in THF/water (10 mL/3 mL) was heated to reflux for 1 h. The
reaction was diluted with EA (100 mL), washed with water (100 mL)
and brine (50 mL), dried, concentrated, and purified on silica gel
(PE/EA, 2:3) to give
(S)-2-(1-amino-4,6-dioxo-4H-thieno[3,4-c]pyrrol-5(6H)-yl)-2-(3-ethoxy-4-m-
ethoxyphenyl)-N,N-dimethylethanesulfonamide (110 mg, 29%) as a
yellow semi-solid. MS (ESI) m/z 439.1[M+H].sup.+.
To a solution of
(S)-2-(1-amino-4,6-dioxo-4H-thieno[3,4-c]pyrrol-5(6H)-yl)-2-(3-ethoxy-4-m-
ethoxyphenyl)-N,N-dimethylethanesulfonamide (110 mg, 0.25 mmol) in
pyridine (6 mL) was added acetyl chloride (198 mg, 2.5 mmol) at
0.degree. C. The mixture was stirred at 0.degree. C. for 2 h. The
reaction was quenched with water (50 mL), extracted with EA (50
mL), the organic phase was washed with 0.5 N HCl (20 mL) and brine
(50 mL). The organic phase was dried over Na.sub.2SO.sub.4,
concentrated, and purified with prep-TLC (PE/EA, 1:1) to give the
title compound (67 mg, 54%) as a white solid. MS (ESI) m/z 496.1
[M+H].sup.+. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.10 (s,
1H), 7.32 (s, 1H), 7.08-7.05 (m, 2H), 6.83 (d, J=8.4 Hz, 1H), 5.74
(dd, J=3.2, 11.2 Hz, 1H), 4.56 (dd, J=11.2, 14.4 Hz, 1H), 4.10 (q,
J=6.8 Hz, 2H), 3.85 (s, 3H), 3.42 (dd, J=3.2, 14.4 Hz, 1H), 2.84
(s, 6H), 2.29 (s, 3H), 1.47 (t, J=6.8 Hz, 3H).
Example 16: Compound 16 (S) and Compound 17 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-
-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)-2,2,2-trifluoro acetamide
##STR00046##
To a solution of 3,4-dihydroxybenzaldehyde (50.0 g, 37.5 mmol) in
DMF (500 mL) was added DCM (50.0 g, 588.9 mmol) and K.sub.2CO.sub.3
(7.76 g, 52.25 mmol). The mixture was heated to 120.degree. C. for
2 h then concentrated and purified on silica gel eluting with EA/PE
from 50% to 70% to give benzo[d][1,3]dioxole-5-carbaldehyde (49 g,
90%) as a black solid. MS (ESI) m/z 151.1 [M+1].sup.+.
A solution of benzo[d][1,3]dioxole-5-carbaldehyde (38.0 g, 253.33
mmol) in DMF (400 mL) was added dimethyl sulfone (59.7 g, 633.33
mmol) and NaOH (15.2 g, 380 mmol). The mixture was heated to
50.degree. C. for 2 h then concentrated and purified on silica gel
eluting with EA/PE from 50% to 80% to give
(E)-5-(2-(methylsulfonyl)vinyl)benzo[d][1,3]dioxole (24.0 g, 44.1%)
as a yellow solid. MS (ESI) m/z 227.3 [M+1].sup.+.
A mixture of (E)-5-(2-(methylsulfonyl)vinyl)benzo[d][1,3]dioxole
(24.0 g, 106.05 mmol) and hydroxylamine (29.1 g, 221.2 mmol) in THF
(200 mL) was heated to reflux for overnight. The mixture was
concentrated and purified on silica gel (PE/EA=80%-100%) to give
N-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)hydroxylamine
(12.0 g, 43.7%) as a colorless oil. MS (ESI) m/z 260.3
[M+1].sup.+.
A mixture of
N-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)
hydroxylamine (12.0 g, 13.78 mmol) and Pd/C (1.2 g) in MeOH (30 mL)
was stirred at RT under H.sub.2 overnight. The mixture was filtered
and the filtrate was concentrated and purified on silica gel
eluting with EA/PE from 80% to 100% to give
1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethanamine (5.4 g,
48%) as a white solid. Chiral prep-HPLC afforded the two
enantiomers as white solids: S isomer (peak 1, 2.53 g, 93.7%); R
isomer (peak 2, 2.5 g, 92.6%). S isomer MS (ESI) m/z 243.3
[M+1].sup.+.
A mixture of 4-nitrothieno[3,4-c]furan-1,3-dione (357 mg, 1.79
mmol), and
(S)-1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethanamine (420
mg, 1.79 mmol) in THF (15 mL) was stirred at RT for 1 h then
1,1'-carbonyldiimidazole (348 mg, 2.15 mmol) was added and the
reaction was heated to reflux for another 1 h. The mixture was
concentrated and the residue was purified on silica gel eluting
with EA/PE from 30% to 50% to give
(S)-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-1-ni-
tro-4H-thieno-[3,4-c]pyrrole-4,6(5H)-dione (630 mg, 83%) as a
yellow solid. MS (ESI) m/z 426.1 [M+1].sup.+.
A mixture of (S)-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)
ethyl)-1-nitro-4H-thieno[3,4-c]pyrrole-4,6(5H)-dione (500 mg, 1.18
mmol), ammonium chloride (375 mg, 7.08 mmol) and iron powder (528
mg, 5.34 mmol) in THF/water (5 mL/2 mL) was heated to reflux for 1
h. The reaction was filtered, concentrated, and purified on silica
gel eluting with EA/PE from 40% to 70% to give
(S)-1-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (160 mg, 35%) as a yellow solid.
MS (ESI) m/z 394.1 [M+H].sup.+.
To a solution of
(S)-1-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[3,4-c]pyrrole-4,6(5H)-dione (160 mg, 0.41 mmol) in ACN (3 mL)
was added pyridine (0.1 mL). The mixture was cooled to 0.degree.
C., then trifluoroacetic anhydride (0.1 mL in 1 mL ACN) was added
dropwise. The mixture was stirred at 0.degree. C. for 0.5 h then
HCl (2M, 3 mL) was added. The organic layer was washed with brine,
dried over Na.sub.2SO.sub.4, concentrated, and purified by
prep-HPLC (ACN/H.sub.2O=5%-95%) to give Compound 16 (49 mg, 24%) as
a white solid. MS (ESI) m/z 508.1 [M+H.sub.2O].sup.+. .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 7.96 (s, 1H), 7.06 (s, 1H), 6.89 (s,
2H), 6.01 (d, J=4.0, 2H), 5.70 (q, 1H), 4.31 (q, 1H), 4.08 (q, 1H),
3.01 (s, 3H). Compound 17 was prepared analogously to Compound 16.
MS (ESI) m/z 508.0 [M+H.sub.2O].sup.+.
Example 17: Compound 21 (S) and Compound 22 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-
-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)-2,2,2-trifluoroacetamide
##STR00047##
To a solution of 3-bromothieno[2,3-c]furan-4,6-dione (317.6 mg,
1.37 mmol) in THF (10 mL) at RT was added
1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethanamine (333 mg,
1.37 mmol). The mixture was stirred for 1 h then
1,1'-carbonyldiimidazol (332.9 mg, 2.06 mol) was added and the
mixture was heated at 70.degree. C. for 1 h. The reaction was
cooled and concentrated. The residue was purified on silica gel
eluting with EA/PE from 10% to 50% to give
5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-3-bromo-4H-thien-
o[2,3-c]pyrrole-4,6(5H)-dione (502 mg, 77.1%) as a light yellow
solid. MS (ESI) m/z 474.8, 476.8. [M+H.sub.2O].sup.+.
To a suspension of
5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-3-bromo-4H-thien-
o[2,3-c]pyrrole-4,6(5H)-dione (316 mg, 0.693 mmol) in
1,4-dioxane/toluene (15 mL/15 mL) at RT was added
diphenylmethanimine (188 mg, 1.04 mmol) and CsCO.sub.3 (450 mg,
1.38 mmol). The suspension was degassed and purged with nitrogen
twice. Tris(dibenzylideneacetone)dipalladium Pd.sub.2(dba).sub.3
(253 mg, 0.277 mmol) and Xantphos (240 mg, 0.416 mmol) was added.
The suspension was heated at 100.degree. C. for 16 h. The reaction
was cooled and concentrated. The residue was purified on silica gel
eluting with EA/PE from 10% to 50% to give
5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-3-((diphenylmeth-
ylene)amino)-4H-thieno[2,3-c]pyrrole-4,6(5H)-dione (241 mg, 39.8%)
as a yellow gum. MS (ESI) m/z 559.0 [M+H].sup.+.
To a solution of
5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-3-((diphenylmeth-
ylene) amino)-4H-thieno[2,3-c]pyrrole-4,6(5H)-dione (163 mg, 0.293
mmol) in MeOH/DCM (8 mL/2 mL) at RT was added hydroxylamine
hydrochloride (81 mg, 1.632 mmol) and NaOAc (120 mg, 1.465 mmol).
The suspension was stirred at RT for 3 h, concentrated, and
purified on silica gel eluting with EA/PE from 10% to 50% to give
3-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-thien-
o[2,3-c]pyrrole-4,6(5H)-dione (83 mg, 48%) as a yellow solid. MS
(ESI) m/z 394.9 [M+H].sup.+.
To a solution of
3-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)
ethyl)-4H-thieno[2,3-c]pyrrole-4,6(5H)-dione (32 mg, 0.081 mmol) in
DCM/pyridine (2 mL/2 mL) at 0.degree. C. was added a solution of
trifluoroacetic anhydride (86 mg, 0.405 mmol) in DCM (0.5 mL). The
reaction was stirred at 0.degree. C. for 10 min, quenched with
water (1 mL), and extracted with DCM. The combined organic layers
were washed with 1N HCl, dried over Na.sub.2SO.sub.4, filtered,
concentrated, and purified by prep-TLC (PE/EA, 1:1) to give the
title compound (26.1 mg, 65.7%) as a light yellow solid. Chiral
prep-HPLC afforded the two enantiomers. (S) enantiomer (21): MS
(ESI) m/z 508.0 [M+H.sub.2O].sup.+; .sup.1H NMR (400 MHz, DMSO-d6)
.delta. 11.71 (s, 1H), 8.18 (s, 1H), 7.08 (s, 1H), 6.91 (s, 2H),
6.02 (dd, J=1.2, 3.6 Hz, 2H), 5.67 (dd, J=4.4, 10.0 Hz, 1H), 4.27
(dd, J=10.8, 14.4 Hz, 1H), 4.09 (dd, J=4.8, 14.4 Hz, 1H), 3.01 (s,
3H). (R) enantiomer (22): MS (ESI) m/z 508.0
[M+H.sub.2O].sup.+.
Example 18: Compound 23 (S) and Compound 24 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-
-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)acetamide
##STR00048##
To a solution of
3-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-thien-
o[2,3-c]pyrrole-4,6(5H)-dione (49 mg, 0.125 mmol) in DCM/pyridine
(2 mL/2 mL) at 0.degree. C. was added a solution of acetyl chloride
(49 mg, 0.623 mmol) in DCM (0.5 mL). The reaction was stirred at
0.degree. C. for 10 min then quenched with water (1 mL) and
extracted with DCM. The combined organic layers were washed with 1
N HCl, dried over Na.sub.2SO.sub.4, filtered, concentrated, and
purified by prep-TLC (PE/EA=1/1) to give the title compound (21.4
mg, 39.5%) as a light yellow solid. Chiral prep-HPLC afforded the
two enantiomers. (S) enantiomer (23): MS (ESI) m/z 437.0
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 10.07 (s, 1H),
8.28 (s, 1H), 7.08 (s, 1H), 6.91 (s, 2H), 6.02 (d, J=2.4 Hz, 2H),
5.68 (dd, J=4.4, 10.4 Hz, 1H), 4.27 (dd, J=10.8, 14.4 Hz, 1H), 4.08
(dd, J=4.4, 14.4 Hz, 1H), 3.02 (s, 3H), 2.11 (s, 3H). (R)
enantiomer (24): MS (ESI) m/z 454.0 [M+H.sub.2O].sup.+.
Example 19: Compound 25 (S) and Compound 26 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4,6-dioxo-5,6-
-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)-2-methoxy acetamide
##STR00049##
To a solution of
3-amino-5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(methylsulfonyl)ethyl)-4H-thien-
o[2,3-c]pyrrole-4,6(5H)-dione (32 mg, 0.081 mmol) in DCM/pyridine
(2 mL/2 mL) at 0.degree. C. was added a solution of 2-methoxyacetyl
chloride (44 mg, 0.407 mmol) in DCM (0.5 mL). The reaction was
stirred at 0.degree. C. for 10 min then quenched with H.sub.2O (1
mL) and extracted with DCM. The combined organic layers were washed
with 1 N HCl, dried over Na.sub.2SO.sub.4, filtered, concentrated,
and purified by prep-TLC (PE/EA, 1:1) to give the title compound
(31.4 mg, 82.8%) as a yellow solid. Chiral prep-HPLC afforded the
two enantiomers. (S) enantiomer (25): MS (ESI) m/z 467.0
[M+H].sup.+. .sup.1H NMR (400 MHz, DMSO-d6) .delta. 9.54 (s, 1H),
8.31 (s, 1H), 7.08 (s, 1H), 6.91 (s, 2H), 6.02 (d, J=2.0 Hz, 2H),
5.67 (dd, J=4.0, 10.0 Hz, 1H), 4.09 (dd, J=4.8, 9.6 Hz, 1H), 4.08
(s, 2H), 3.42 (s, 3H), 3.02 (s, 3H). (R) enantiomer (26): MS (ESI)
m/z 484.1 [M+H.sub.2O].sup.+.
Example 20: Compound 27 (S) and Compound 28 (R):
N-(5-(1-(benzo[d][1,3]dioxol-5-yl)-2-(N,N-dimethylsulfamoyl)ethyl)-4,6-di-
oxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-1-yl)acetamide
##STR00050##
A solution of benzo[d][1,3]dioxole-5-carbaldehyde (8.0 g, 53.33
mmol) in DMF (100 mL) was added N,N-dimethylmethanesulfonamide
(16.5 g, 133.33 mmol) and NaOH (3.2 g, 80 mmol). The mixture was
heated at 50.degree. C. for 2 h, concentrated, and purified on
silica gel (PE/EA, 50%-80%) to give (E)-2-(benzo[d][1,3]
dioxol-5-yl)-N,N-dimethylethenesulfonamide (6.2 g, 45.5%) as a
yellow solid. MS (ESI) m/z 256.3 [M+1].sup.+.
A mixture of (E)-2-(benzo[d][1,3]dioxol-5-yl)-N,N-dimethylethene
sulfonamide (6.2 g, 24.29 mmol) and NH.sub.2OH (7.3 g, 221.2 mmol)
in THF (50 mL) was heated to reflux overnight. The mixture was
concentrated and purified on silica gel (PE/EA, 80%-100%) to give
2-(benzo[d][1,3]dioxol-5-yl)-2-(hydroxyamino)-N,N-dimethylethane
sulfonamide (3.6 g, 51.4%) as a colorless oil. MS (ESI) m/z 289.3
[M+1].sup.+.
A mixture of
2-(benzo[d][1,3]dioxol-5-yl)-2-(hydroxyamino)-N,N-dimethylethanesulfonami-
de (3.6 g, 13.78 mmol) and Pd/C (360 mg) in MeOH (30 mL) was
stirred at RT under H.sub.2 overnight. The mixture was filtered,
concentrated, and purified on silica gel (PE/EA, 80%-100%) to give
2-amino-2-(benzo[d][1,3]dioxol-5-yl)-N,N-dimethylethanesulfonamide
(3 g, 89%) as a white solid. MS (ESI) m/z 273.3 [M+1].sup.+.
A mixture of
2-amino-2-(benzo[d][1,3]dioxol-5-yl)-N,N-dimethylethane sulfonamide
(3 g, 11.02 mmol) and di-tert-butyl dicarbonate (3.6 g, 16.51 mmol)
in MeOH (30 mL) was stirred at RT overnight. The mixture was
concentrated and purified on silica gel (PE/EA, 80%-100%) to give
tert-butyl(1-(benzo[d][1,3]dioxol-5-yl)-2-(N,N-dimethyl
sulfamoyl)ethyl)carbamate (2.8 g, 68.3%) as a colorless oil. Chiral
prep-HPLC afforded the two enantiomers as white solids: S isomer
(peak 1, 1.33 g, 95%); R isomer (peak 2, 1.3 g, 92.9%). S isomer MS
(ESI) m/z 373.4 [M+1].sup.+.
A mixture of 4-nitrothieno[3,4-c]furan-1,3-dione (630 mg, 2.32
mmol) and
(S)-2-amino-2-(benzo[d][1,3]dioxol-5-yl)-N,N-dimethylethanesulfonamide
(390 mg, 1.96 mmol) in THF (10 mL) was stirred at RT for 1 h then
1,1'-carbonyldiimidazol (381 mg, 2.35 mmol) was added. The reaction
was heated to reflux for another 1 h then concentrated and purified
on silica gel (PE/EA, 30%-50%) to give
(S)-2-(benzo[d][1,3]dioxol-5-yl)-N,N-dimethyl-2-(1-nitro-4,6-dioxo-4H-thi-
eno[3,4-c]pyrrol-5(6H)-yl)ethanesulfonamide (420 mg, 47%) as a
yellow solid. MS (ESI) m/z 453.9 [M+1].sup.+.
A mixture of
(S)-2-(benzo[d][1,3]dioxol-5-yl)-N,N-dimethyl-2-(1-nitro-4,6-dioxo-4H-thi-
eno[3,4-c]pyrrol-5(6H)-yl)ethanesulfonamide (440 mg, 0.97 mmol),
ammonium chloride (309 mg, 5.83 mmol) and iron powder (326 mg, 5.83
mmol) in THF/water (5 mL/2 mL) was heated to reflux for 1 h. The
mixture was filtered, concentrated, purified on silica gel (PE/EA,
40%-70%) to give
(S)-2-(1-amino-4,6-dioxo-4H-thieno[3,4-c]pyrrol-5(6H)-yl)-2-(benzo[d][1,3-
]dioxol-5-yl)-N,N-dimethylethanesulfonamide (148 mg, 34%) as a
yellow solid. MS (ESI) m/z 453.1[M+H].sup.+.
To a solution of
(S)-2-(1-amino-4,6-dioxo-4H-thieno[3,4-c]pyrrol-5(6H)-yl)-2-(benzo[d][1,3-
]dioxol-5-yl)-N,N-dimethylethanesulfonamide (148 mg, 0.33 mmol) in
DCM (3 mL) was added pyridine (0.1 mL). The mixture was cooled to
0.degree. C. then acetyl chloride (0.1 mL in 1 mL ACN) was added
dropwise. The mixture was stirred at 0.degree. C. for 0.5 h. HCl
(2M, 3 mL) was added then the organic layer was washed with brine,
dried over Na.sub.2SO.sub.4, concentrated and purified by prep-HPLC
(ACN/H.sub.2O, 5%-95%) to give Compound 27 (65 mg, 43%) as a white
solid. MS (ESI) m/z 466.0 [M+H].sup.+. .sup.1H NMR (400 MHz,
DMSO-d6) .delta. 11.73 (s, 1H), 7.76 (s, 1H), 7.09 (s, 1H), 6.90
(s, 2H), 6.02 (d, J=4.0, 2H), 5.62 (q, 1H), 4.30-4.31 (m, 1H),
3.45-3.48 (m, 1H), 2.77 (s, 6H), 2.24 (s, 1H). Compound 28 was
prepared analogously to Compound 27. MS (ESI) m/z 483.1
[M+H.sub.2O].sup.+.
Example 21: Compound 29:
(R)--N-(5-(2-(N,N-dimethylsulfamoyl)-1-(3-ethoxy-4-methoxyphenyl)ethyl)-4-
,6-dioxo-5,6-dihydro-4H-thieno[3,4-c]pyrrol-yl)acetamide
##STR00051##
A mixture of
(R)-2-(3-ethoxy-4-methoxyphenyl)-N,N-dimethyl-2-(1-nitro-4,6-dioxo-4H-thi-
eno[3,4-c]pyrrol-5(6H)-yl)ethanesulfonamide (410 mg, 0.85 mmol),
ammonium chloride (228 mg, 4.25 mmol) and iron powder (238 mg, 4.25
mmol) in THF/water (10 mL/3 mL) was heated to reflux for 1 h. The
reaction was diluted with EA (100 mL), washed with water (100 mL)
and brine (50 mL), dried over Na.sub.2SO.sub.4, concentrated, and
purified on silica gel (PE/EA, 2:3) to give
(R)-2-(1-amino-4,6-dioxo-4H-thieno-[3,4-c]pyrrol-5(6H)-yl)-2-(3-ethoxy-4--
methoxyphenyl)-N,N-dimethylethanesulfonamide (110 mg, 29%) as a
yellow semi-solid. MS (ESI) m/z 439.1 [M+H].sup.+.
To a solution of
(R)-2-(1-amino-4,6-dioxo-4H-thieno[3,4-c]pyrrol-5(6H)-yl)-2-(3-ethoxy-4-m-
ethoxyphenyl)-N,N-dimethylethanesulfonamide (110 mg, 0.25 mmol) in
pyridine (6 mL) was added acetyl chloride (198 mg, 2.5 mmol) at
0.degree. C., and stirred at 0.degree. C. for 2 h. The reaction was
quenched with water (50 mL), extracted with EA (50 mL), and the
organic phase was washed with 0.5N HCl (20 mL) and brine (50 mL).
The organic phase was dried over Na.sub.2SO.sub.4, concentrated,
and purified with prep-TLC (PE/EA, 1:1) to give the title compound
(67 mg, 54%) as a white solid. MS (ESI) m/z 496.1 [M+H].sup.+.
.sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.10 (s, 1H), 7.32 (s,
1H), 7.08-7.05 (m, 2H), 6.83 (d, J=8.4 Hz, 1H), 5.74 (dd, J=3.2,
11.2 Hz, 1H), 4.56 (dd, J=11.2, 14.4 Hz, 1H), 4.10 (q, J=6.8 Hz,
2H), 3.85 (s, 3H), 3.42 (dd, J=3.2, 14.4 Hz, 1H), 2.84 (s, 6H),
2.29 (s, 3H), 1.47 (t, J=6.8 Hz, 3H).
Example 22: Compound 30:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-6-oxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)-2,2,2-trifluoroacet-
amide
##STR00052##
To a stirred solution of methyl
4-bromo-3-(bromomethyl)thiophene-2-carboxylate (628 mg, 2 mmol) and
(S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethanamine (819
mg, 3.0 mmol) in ACN (20 mL) was added CsCO.sub.3 (358 mg, 1.1
mmol). The mixture was stirred at RT overnight then concentrated
and purified on silica gel (PE/EA, 1:1) to give
(S)-methyl-4-bromo-3-(((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)et-
hyl)amino)methyl)thiophene-2-carboxylate (905 mg, 90%) as yellow
solid. MS (ESI) m/z 505.9 [M+H].sup.+.
To a stirred solution of
(S)-methyl4-bromo-3-(((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)eth-
yl)amino)methyl)thiophene-2-carboxylate (740 mg, 1.46 mmol) in THF
(8 mL) and MeOH (8 mL) was added a solution of lithium hydroxide
(614 mg, 14.6 mmol) in water (8 mL). The mixture was stirred at RT
for 8 h then concentrated. The pH was adjusted to 4 with 2 N HCl
and the mixture extracted with DCM. The organic layer was washed
with brine, dried over Na.sub.2SO.sub.4, and evaporated to give
(S)-4-bromo-3-(((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)ami-
no)methyl)thiophene-2-carboxylic acid (638 mg, 89%) as a yellow
solid. MS (ESI) m/z 491.9 [M+H].sup.+.
To a stirred solution of
(S)-4-bromo-3-(((1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)ami-
no)methyl)thiophene-2-carboxylic acid (628 mg, 1.27 mmol) in DCM
(20 mL) was added oxalyl chloride (486 mg, 3.8 mmol) dropwise then
2 drops of DMF was added. The mixture was stirred at RT overnight
then concentrated and purified on silica gel (DCM/MeOH, 10:1) to
give
(S)-3-bromo-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrol-6(5H)-one (398 mg, 66%) as a white solid. MS
(ESI) m/z 473.9 [M+H].sup.+.
To a stirred solution of
(S)-3-bromo-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrol-6(5H)-one (364 mg, 0.77 mmol) and
diphenylmethanimine (183 mg, 1.01 mmol) in 1,4-dioxane (3.5 mL) and
toluene (3.5 mL) was added CsCO.sub.3 (511 mg, 1.56 mmol) and
tris(dibenzylideneacetone)dipalladium Pd.sub.2(dba).sub.3 (73 mg,
0.08 mmol) and Xantphos (110 mg, 0.21 mmol). The mixture was
stirred at 108.degree. C. (microwave) for 16 h. The mixture was
diluted with water and EA. The organic layer was separated and
washed with brine, dried by Na.sub.2SO.sub.4, filtered, evaporated,
and purified by prep-TLC (Petroleum/EA, 1:1) to give
(S)-3-((diphenylmethylene)amino)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methy-
lsulfonyl)ethyl)-4H-thieno[2,3-c]pyrrol-6(5H)-one (140 mg, 32%) as
a yellow solid. MS (ESI) m/z 575.0 [M+H].sup.+.
To a stirred solution of
(S)-3-((diphenylmethylene)amino)-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methy-
lsulfonyl)ethyl)-4H-thieno[2,3-c]pyrrol-6(5H)-one (140 mg, 0.24
mmol) in EA (5 mL) was added a solution of HCl in EA (2.5 mL). The
mixture was stirred at RT for 20 min then concentrated and washed
with petroleum to give
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-
-4H-thieno[2,3-c]pyrrol-6(5H)-one (130 mg crude) as a yellow solid.
MS (ESI) m/z 411.0 [M+H].sup.+.
To a stirred solution of
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrol-6(5H)-one (25 mg, 0.06 mmol) in DCM (1 mL) and
pyridine (1 mL) was added a solution of trifluoroacetylchloride (38
mg, 0.18 mmol) in DCM (0.1 mL) at 0.degree. C. The mixture was
stirred at 0.degree. C. for 30 min then quenched with water and
extracted with EA. The organic layer was washed with 1 N HCl then
brine, and dried over Na.sub.2SO.sub.4, evaporated, and purified by
prep-TLC (petroleum/EA, 1:1) to give the title compound (4 mg, 33%)
as a white solid. MS (ESI) m/z 507.0 [M+H].sup.+. .sup.1H NMR (400
MHz, DMSO-d6) .delta. 7.92 (s, 1H), 6.99-6.92 (m, 3H), 5.82-5.78
(m, 1H), 4.54 (d, J=19.2 Hz, 1H), 4.27-4.21 (m, 1H), 4.13-4.08 (m,
1H), 4.05-3.98 (m, 2H), 3.96-3.91 (m, 1H), 3.74 (s, 3H), 3.01 (s,
3H), 1.74-1.72 (m, 1H), 1.31 (t, J=6.8 Hz, 3H).
Example 23: Compound 31:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-6-oxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)-2-methoxyacetamide
##STR00053##
To a stirred solution of
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrol-6(5H)-one (30 mg, 0.073 mmol) in DCM (1 mL) and
pyridine (1 mL) was added a solution of 2-methoxyacetyl chloride
(24 mg, 0.22 mmol) in DCM (0.1 mL) at 0.degree. C. The mixture was
stirred at 0.degree. C. for 20 min then quenched with water and
extracted with EA. The organic layer was washed with 1 N HCl, then
brine, and dried by Na.sub.2SO.sub.4, evaporated, and purified by
prep-TLC (petroleum/EA, 1:2) to give the title compound (18 mg,
57%) as a white solid. MS (ESI) m/z 483.1 [M+H].sup.+. .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 10.24 (s, 1H), 7.77 (s, 1H), 6.98-6.91
(m, 3H), 5.81-5.77 (m, 1H), 4.49 (d, J=18.4 Hz, 1H), 4.24-4.18 (m,
1H), 4.12-4.08 (m, 1H), 4.05-3.92 (m, 5H), 3.74 (s, 3H), 3.35 (s,
3H), 3.00 (s, 3H), 1.31 (t, J=6.8 Hz, 3H).
Example 24: Compound 32:
(S)--N-(5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)
ethyl)-6-oxo-5,6-dihydro-4H-thieno[2,3-c]pyrrol-3-yl)cyclopropanecarboxam-
ide
##STR00054##
To a stirred solution of
(S)-3-amino-5-(1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-4H-t-
hieno[2,3-c]pyrrol-6(5H)-one (40 mg, 0.098 mmol) in DCM (1 mL) and
pyridine (1 mL) was added a solution of cyclopropanecarbonyl
chloride (0.35 mmol) in D